vigabatrin has been researched along with Cryptogenic Infantile Spasms in 291 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This systematic review and meta-analysis aimed to evaluate the efficacy of vigabatrin (VGB) in treating infantile epileptic spasms syndrome (IESS)." | 9.41 | Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. ( Chang, X; Gong, P; Jiao, X; Niu, Y; Wu, Y; Xu, Z; Yang, Z; Zhang, Y, 2023) |
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 9.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "To evaluate the efficacy of vigabatrin (VGB) in the treatment of infantile spasms (ISs) associated with Down syndrome (DS) and to assess the feasibility of early discontinuation to reduce the possible retinal toxicity." | 9.09 | Infantile spasms in Down syndrome: good response to a short course of vigabatrin. ( Akatcherian, C; Dulac, O; Gerbaka, B; Melki, I; Nabbout, R, 2001) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 9.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 8.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries for the treatment of partial and secondarily generalized seizures." | 8.80 | The potential for vigabatrin-induced intramyelinic edema in humans. ( Brigell, MG; Cohen, JA; Fisher, RS; Peyster, RG; Sze, G, 2000) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 8.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "To report response to first treatment in infants with infantile spasms (IS), including incremental benefit of prednisolone 60 mg/day and vigabatrin following prednisolone 40 mg/day failure in infants commenced on the United Kingdom Infantile Spasms Study (UKISS) treatment sequence." | 8.12 | Response to sequential treatment with prednisolone and vigabatrin in infantile spasms. ( Cheng, S; Dzau, W; Fahey, M; Harvey, AS; Howell, KB; Scheffer, IE; Snell, P, 2022) |
| "Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS)." | 8.02 | What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? ( Arbour, M; Bello-Espinosa, L; Birca, A; Bitton, JY; Desnous, B; Lenoir, M; Lortie, A; Mohammed, I; Ronen, GM; Villeneuve, N; Whiting, S; Wirrell, EC, 2021) |
| "Objective: To evaluate the effects and tolerability of vigabatrin (VGB) in children with tuberous sclerosis (TS) with infantile spasms or tonic seizures." | 7.83 | Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms. ( Hino-Fukuyo, N; Kiluchi, A; Kobayashi, T; Kure, S; Nakayama, T; Numata-Uematsu, Y; Sato, H; Suzuki-Muromoto,, S; Uematsu, M, 2016) |
| "This retrospective study reviewed the Hospital for Sick Children's experience with the short-term efficacy of vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex." | 7.81 | Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. ( Boyd, J; Go, C; Jones, K; McCoy, B; Ochi, A; Puka, K; Snead, OC, 2015) |
| "We aimed to investigate the relationship between movement disorders, changes on brain magnetic resonance imaging (MRI), and vigabatrin therapy in children with infantile spasms." | 7.79 | An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. ( Edwards, SW; Fong, CY; Hancock, E; Hemingway, C; Johnson, AL; Kennedy, CR; Kneen, R; Likeman, M; Lux, AL; Mordekar, SR; Murugan, V; Newton, RW; O'Callaghan, FJ; Osborne, JP; Pike, M; Quinn, M; Spinty, S; Vassallo, G; Verity, CM; Whitney, A, 2013) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 7.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 7.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| "Vigabatrin (VGB) is one of the most effective anti-epileptic drugs for tonic spasms, those accompanied with tuberous sclerosis complex (TSC), but is not available in Japan." | 7.76 | [Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis]. ( Ando, N; Fujimoto, S; Hattori, A; Ishikawa, T; Ito, T; Kobayashi, S; Togari, H, 2010) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 7.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "To report the efficacy of vigabatrin in seizures control, as well as the electroencephalographic abnormalities in children with tuberous sclerosis and West syndrome." | 7.72 | [Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis]. ( da Silva, AR; Ohlweiler, L; Riesgo, R; Rotta, NT, 2003) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 7.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 7.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 6.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 6.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| " For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vigabatrin after response." | 5.48 | High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. ( Bebin, EM; Goyal, M; Hussain, SA; Krueger, DA; Northrup, H; Peters, JM; Sahin, M; Schmid, E; Wu, JY, 2018) |
| "This systematic review and meta-analysis aimed to evaluate the efficacy of vigabatrin (VGB) in treating infantile epileptic spasms syndrome (IESS)." | 5.41 | Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. ( Chang, X; Gong, P; Jiao, X; Niu, Y; Wu, Y; Xu, Z; Yang, Z; Zhang, Y, 2023) |
| "Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy." | 5.41 | Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. ( Aronica, E; Benova, B; Borkowska, J; Curatolo, P; de Ridder, J; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Hulshof, H; Jansen, AC; Jansen, F; Jóźwiak, S; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Moavero, R; Nabbout, R; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Weschke, B; Wojdan, K, 2021) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 5.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 5.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients." | 5.12 | Vigabatrin - new data on indications and safety in paediatric epilepsy. ( Golec, W; Jóźwiak, S; Jurkiewicz, E; Sołowiej, E; Strzelecka, J, 2021) |
| "The objective of this study was to compare the efficacy of corticotropin (ACTH) versus vigabatrin in treating infantile spasms and to determine which medication has a more favorable long-term outcome in terms of cognitive function, evolution of epilepsy, and incidence of autism." | 5.10 | Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. ( Askalan, R; Boyd, J; Brian, J; Bryson, S; Mackay, M; McDermott, C; Otsubo, H; Roberts, W; Snead, C; Weiss, S, 2003) |
| "To evaluate the efficacy of vigabatrin (VGB) in the treatment of infantile spasms (ISs) associated with Down syndrome (DS) and to assess the feasibility of early discontinuation to reduce the possible retinal toxicity." | 5.09 | Infantile spasms in Down syndrome: good response to a short course of vigabatrin. ( Akatcherian, C; Dulac, O; Gerbaka, B; Melki, I; Nabbout, R, 2001) |
| "Vigabatrin has been shown to be efficient in infants with infantile spasms and tuberous sclerosis, in open studies." | 5.08 | Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 1997) |
| "The purpose of this report is to review the efficacy and safety of vigabatrin in the treatment of infantile spasms in infants suffering from tuberous sclerosis complex." | 4.80 | Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. ( Hancock, E; Osborne, JP, 1999) |
| "Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries for the treatment of partial and secondarily generalized seizures." | 4.80 | The potential for vigabatrin-induced intramyelinic edema in humans. ( Brigell, MG; Cohen, JA; Fisher, RS; Peyster, RG; Sze, G, 2000) |
| "More than 360 children with intractable epilepsy have been treated with vigabatrin in single-blind or open, add-on studies." | 4.78 | The role of vigabatrin in the management of infantile epileptic syndromes. ( Appleton, RE, 1993) |
| "To describe the temporal trends in the cost and use of adrenocorticotropic hormone (ACTH), oral prednisolone, and vigabatrin, the first-line treatments for infantile epileptic spasms syndrome (IESS)." | 4.31 | Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome. ( Amengual-Gual, M; Barcia Aguilar, C; Chao, J; Douglass, L; Gaínza-Lein, M; Harini, C; Jonas, R; Romeu, A; Sánchez Fernández, I; Sheikh, T; Torres, A, 2023) |
| "To report a prospectively planned analysis of two randomised controlled trials with embedded comparisons of prednisolone versus tetracosactide depot for the treatment of infantile epileptic spasms syndrome (IESS)." | 4.31 | Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials. ( Alber, FD; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2023) |
| "We evaluated patients with ES from the CDKL5 Centers of Excellence and the National Infantile Spasms Consortium (NISC), with onset from 2 months to 2 years, treated with adrenocorticotropic hormone (ACTH), oral corticosteroids, vigabatrin, and/or the ketogenic diet." | 4.31 | Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies. ( Benke, T; Daniels, C; DeLeo, M; Demarest, S; Greene, C; Harini, C; Haviland, I; Katyayan, A; Love-Nichols, J; Marsh, ED; Moosa, AN; O'Connor Prange, E; Olson, HE; Pérez-Pérez, JR; Pestana-Knight, E; Poduri, A; Rajaraman, RR; Suter, B; Swanson, L; Weisenberg, J; Zhang, B; Zhang, X, 2023) |
| "Prednisolone is an effective and well-tolerated medication for treating infantile spasms in Down syndrome." | 4.12 | Response to treatment and outcomes of infantile spasms in Down syndrome. ( Allen, NM; Gorman, KM; Harvey, S; King, MD; Lynch, B; Lynch, SA; O'Regan, M; O'Rourke, D; Shahwan, A; Webb, D, 2022) |
| "To report response to first treatment in infants with infantile spasms (IS), including incremental benefit of prednisolone 60 mg/day and vigabatrin following prednisolone 40 mg/day failure in infants commenced on the United Kingdom Infantile Spasms Study (UKISS) treatment sequence." | 4.12 | Response to sequential treatment with prednisolone and vigabatrin in infantile spasms. ( Cheng, S; Dzau, W; Fahey, M; Harvey, AS; Howell, KB; Scheffer, IE; Snell, P, 2022) |
| "Vigabatrin (VGB) is approved as monotherapy for pediatric patients with Infantile Spasms (IS)." | 4.02 | What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? ( Arbour, M; Bello-Espinosa, L; Birca, A; Bitton, JY; Desnous, B; Lenoir, M; Lortie, A; Mohammed, I; Ronen, GM; Villeneuve, N; Whiting, S; Wirrell, EC, 2021) |
| " Stroke and infarct have a better outcome than other etiologies, whereas Down syndrome might not respond to the addition of vigabatrin to hormonal treatment." | 3.91 | The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (ICISS). ( Dietrich Alber, F; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, M; Mallick, A; Newton, RW; Nolan, M; O'Callaghan, FJK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2019) |
| "Objective: To evaluate the effects and tolerability of vigabatrin (VGB) in children with tuberous sclerosis (TS) with infantile spasms or tonic seizures." | 3.83 | Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms. ( Hino-Fukuyo, N; Kiluchi, A; Kobayashi, T; Kure, S; Nakayama, T; Numata-Uematsu, Y; Sato, H; Suzuki-Muromoto,, S; Uematsu, M, 2016) |
| "This retrospective study reviewed the Hospital for Sick Children's experience with the short-term efficacy of vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex." | 3.81 | Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. ( Boyd, J; Go, C; Jones, K; McCoy, B; Ochi, A; Puka, K; Snead, OC, 2015) |
| "We aimed to investigate the relationship between movement disorders, changes on brain magnetic resonance imaging (MRI), and vigabatrin therapy in children with infantile spasms." | 3.79 | An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. ( Edwards, SW; Fong, CY; Hancock, E; Hemingway, C; Johnson, AL; Kennedy, CR; Kneen, R; Likeman, M; Lux, AL; Mordekar, SR; Murugan, V; Newton, RW; O'Callaghan, FJ; Osborne, JP; Pike, M; Quinn, M; Spinty, S; Vassallo, G; Verity, CM; Whitney, A, 2013) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 3.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 3.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| "To determine whether a new model of cryptogenic infantile spasms consisting of prenatal priming with betamethasone and postnatal trigger of spasms by N-methyl-D-aspartate (NMDA) responds to chronic adrenocorticotropic hormone (ACTH) treatment, and has electroencephalography (EEG) signature, efficacy of treatments, and behavioral impairments similar to those in human infantile spasms." | 3.77 | Validation of the rat model of cryptogenic infantile spasms. ( Chachua, T; Velíšek, L; Velíšková, J; Yum, MS, 2011) |
| "Vigabatrin (VGB) is one of the most effective anti-epileptic drugs for tonic spasms, those accompanied with tuberous sclerosis complex (TSC), but is not available in Japan." | 3.76 | [Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis]. ( Ando, N; Fujimoto, S; Hattori, A; Ishikawa, T; Ito, T; Kobayashi, S; Togari, H, 2010) |
| "From 1 January 1995 to 31 December 2004, 22 patients (13 males, nine females; age range 2-12mo) with infantile spasms and cytomegalovirus (CMV) infection were treated with intravenous ganciclovir (GCV) and antiepileptic drugs." | 3.74 | Infantile spasms and cytomegalovirus infection: antiviral and antiepileptic treatment. ( Dunin-Wasowicz, D; Jurkiewicz, E; Kapusta, M; Kasprzyk-Obara, J; Milewska-Bobula, B, 2007) |
| "To review the result of the infantile spasms' treatment with sodium valproate followed by nitrazepam or clonazepam." | 3.74 | Treatment of infantile spasms with sodium valproate followed by benzodiazepines. ( Auvichayapat, N; Auvichayapat, P; Tassniyom, S; Treerotphon, S, 2007) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 3.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "To report the efficacy of vigabatrin in seizures control, as well as the electroencephalographic abnormalities in children with tuberous sclerosis and West syndrome." | 3.72 | [Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis]. ( da Silva, AR; Ohlweiler, L; Riesgo, R; Rotta, NT, 2003) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 3.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "Seizures in a term infant with Ohtahara syndrome, associated with polymicrogyria, and a pre-term neonate with similar clinical features, failed to respond to conventional anticonvulsants, but were controlled with vigabatrin monotherapy." | 3.69 | Vigabatrin monotherapy in resistant neonatal seizures. ( Barwick, DD; Baxter, PS; Gardner-Medwin, D; Ince, P; Livingston, J; Murdoch-Eaton, D, 1995) |
| "We present the results of treatment with vigabatrin in the polytherapy of resistant infantile epilepsy." | 3.69 | [Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients]. ( Hernández-Laín, A; López-Valdés, E; Mateos, F; Porta, J; Simón, R, 1996) |
| "Three large studies, all including more than 60 children, on the efficacy on gamma-vinyl GABA (vigabatrin, GVG) in the treatment of childhood epilepsy have been reviewed." | 3.68 | Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin). ( Dulac, O; Gram, L; Sabers, A, 1992) |
| "Rapid diagnosis and effective treatment of infantile spasms could therefore improve outcomes." | 2.87 | Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. ( Alber, FD; Cortina Borja, M; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Likeman, M; Lux, AL; Mackay, MT; Mallick, AA; Newton, RW; Nolan, M; O'Callaghan, FJK; Osborne, JP; Pressler, R; Rating, D; Schmitt, B; Verity, CM, 2018) |
| " The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep." | 2.82 | Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. ( Schubert-Bast, S; Strzelczyk, A, 2022) |
| "The better and earlier the seizure control, the better the child's subsequent cognitive and behavioral prognosis." | 2.82 | Overview of therapeutic options for epilepsy. ( Chiron, C; Kuchenbuch, M; Milh, M, 2022) |
| "Infantile spasms are seizures associated with a severe epileptic encephalopathy presenting in the first 2 years of life, and optimal treatment continues to be debated." | 2.82 | Response to treatment in a prospective national infantile spasms cohort. ( Berg, AT; Coryell, J; Dlugos, D; Gaillard, WD; Grinspan, Z; Hamikawa, L; Hartman, AL; Joshi, S; Knupp, KG; Kossoff, EH; Leister, E; Loddenkemper, T; Millichap, J; Mytinger, JR; Nickels, KC; Nordli, DR; Ryan, N; Shellhaas, RA; Sullivan, J; Wirrell, E, 2016) |
| "Both prompt diagnosis and prompt treatment of infantile spasms may help prevent subsequent developmental delay." | 2.76 | The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. ( Darke, K; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2011) |
| "Infantile spasms is the name given to a difficult to treat, severe infantile epilepsy with high morbidity." | 2.75 | Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. ( Darke, K; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2010) |
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 2.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| "Interictal EEG showed hypsarrhythmia in 27 infants and multifocal spikes with normal or nearly normal background in 17 infants." | 2.70 | Infantile spasms: diagnosis and assessment of treatment response by video-EEG. ( Gaily, E; Granström, ML; Liukkonen, E; Paetau, R; Rekola, R, 2001) |
| "Vigabatrin was well tolerated and safe; only nine patients discontinued therapy because of adverse events." | 2.70 | Randomized trial of vigabatrin in patients with infantile spasms. ( Elterman, RD; Mansfield, KA; Nakagawa, J; Shields, WD, 2001) |
| " The dosage was escalated by 25 mg/kg weekly until spasms ceased or the maximum dose of 130 mg/kg was reached." | 2.69 | Vigabatrin in infantile spasms: preliminary result. ( Chiemchanya, S; Phusirimongkol, S; Visudhiphan, P; Visudtibhan, A, 1999) |
| "Vigabatrin (VGB) has been shown to be an effective drug in the treatment of infantile spasms (West syndrome) in predominantly retrospective and open but also in prospective studies." | 2.69 | Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. ( Appleton, RE; Mumford, JP; Peters, AC; Shaw, DE, 1999) |
| "Vigabatrin was given as the initial monotherapy at therapeutic dose of 50-100 mg/kg." | 2.68 | Vigabatrin as first line therapy in infantile spasms: review of seven patients. ( Kwong, L, 1997) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 2.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "Children with infantile spasms are likely to have a poor outcome." | 2.66 | Infantile Spasms: Outcome in Clinical Studies. ( Riikonen, R, 2020) |
| "The first one is represented by West Syndrome (WS): ES occur in a previously non encephalopathic infant in association with the development of a hypsarrhythmic EEG pattern." | 2.66 | Three different scenarios for epileptic spasms. ( Fusco, L; Santarone, ME; Serino, D, 2020) |
| "Vigabatrin is the treatment of choice when the underlying cause is tuberous sclerosis complex (TSC)." | 2.53 | Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy. ( Appleton, R; Iyer, A, 2016) |
| " The efficacy and adverse events of ACTH with different dosage regimens were reviewed and analyzed." | 2.49 | Adrenocorticotropic hormone for the treatment of West Syndrome in children. ( Lam, WM; Manasco, KB; Shumiloff, NA, 2013) |
| "Vigabatrin may be the treatment of choice in tuberous sclerosis." | 2.49 | Treatment of infantile spasms. ( Edwards, SW; Hancock, EC; Osborne, JP, 2013) |
| "Infantile spasms (IS; West syndrome) is a severe form of encephalopathy that typically affects infants younger than 2 years old." | 2.48 | Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. ( Gibson, PA; Hardin, M; O'Dell, C; Pellock, JM; Rosbeck, KL; Wheless, JW; Whittemore, V, 2012) |
| "The mainstay of treatment for infantile spasms is adrenocorticotropic hormone; however, vigabatrin, a vinyl derivative of γ-aminobutyric acid, has been used for the treatment of infantile spasms in Europe since 1989." | 2.47 | Vigabatrin for infantile spasms. ( Belliveau, P; Pesaturo, KA; Spooner, LM, 2011) |
| "Vigabatrin was rationally designed to have a specific effect on brain chemistry by inhibiting the GABA-degrading enzyme, GABA transaminase, resulting in a widespread increase in GABA concentrations in the brain." | 2.47 | Mechanism of action of vigabatrin: correcting misperceptions. ( Ben-Menachem, E, 2011) |
| "Vigabatrin was generally well-tolerated with few severe adverse events." | 2.47 | Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. ( Carmant, L, 2011) |
| "Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid (GABA) transaminase." | 2.47 | Understanding and interpreting vision safety issues with vigabatrin therapy. ( Plant, GT; Sergott, RC, 2011) |
| "Vigabatrin is an effective antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS)." | 2.47 | Non-vision adverse events with vigabatrin therapy. ( Kälviäinen, R; Walker, SD, 2011) |
| "Vigabatrin is an effective and well-tolerated antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS), but its benefits must be evaluated in conjunction with its risk of retinopathy with the development of peripheral visual field defects (pVFDs)." | 2.47 | Balancing clinical benefits of vigabatrin with its associated risk of vision loss. ( Pellock, JM, 2011) |
| "Early treatment of infantile spasms seems to be important." | 2.46 | Favourable prognostic factors with infantile spasms. ( Riikonen, RS, 2010) |
| "Infantile spasms are the classical seizure type of West syndrome." | 2.46 | Modeling new therapies for infantile spasms. ( Betancourth, D; Chudomelova, L; Coppola, A; Galanopoulou, AS; Raffo, E; Scantlebury, MH, 2010) |
| "Vigabatrin (VGB) is a structural analogue of gamma-aminobutyric acid (GABA) that irreversibly inhibits GABA-transaminase (GABA-T), increasing brain levels of GABA." | 2.45 | Vigabatrin: 2008 update. ( Abelson, MB; Ben-Menachem, E; Pellock, JM; Shields, WD; Willmore, LJ, 2009) |
| "Vigabatrin (Sabril) was approved in the USA in mid-2009 for the adjunctive treatment of refractory complex partial seizures and as treatment of infantile spasms." | 2.45 | Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. ( Faulkner, MA; Tolman, JA, 2009) |
| "Although West syndrome is well known clinical epileptic syndrome, there is no agreement about the first- and second-line treatments." | 2.44 | Update of the medical treatment of West syndrome. ( Chiarelli, F; Coppola, GG; Iannetti, P; Manco, R; Mingione, S; Verrotti, A, 2007) |
| "Vigabatrin has emerged as an accepted first-line medication for infantile spasms in Norway and many other countries, although it has not been shown that this therapy in general is as effective as ACTH/steroids." | 2.43 | [Infantile spasms]. ( Nustad, A; Rasmussen, M; Sandvig, I; Skjeldal, OH, 2005) |
| "Adrenocorticotropic hormone (ACTH) is probably effective for the short-term treatment of infantile spasms, but there is insufficient evidence to recommend the optimum dosage and duration of treatment." | 2.42 | Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. ( Adams-Webber, T; Ashwal, S; Ballaban-Gill, K; Baram, TZ; Duchowny, M; Hirtz, D; Mackay, MT; Pellock, JM; Shields, WD; Shinnar, S; Snead, OC; Stephens, D; Weiss, SK; Wyllie, E, 2004) |
| "Vigabatrin has shown promise in treating IS patients, particularly those with tuberous sclerosis." | 2.42 | Pharmacologic treatment of the catastrophic epilepsies. ( Conry, JA, 2004) |
| "ACTH should be the first choice for treatment of infantile spasms." | 2.42 | Infantile spasms: therapy and outcome. ( Riikonen, R, 2004) |
| "Vigabatrin has been shown to be particularly effective in treating infantile spasms in the setting of tuberous sclerosis complex." | 2.42 | Managing epilepsy in tuberous sclerosis complex. ( Thiele, EA, 2004) |
| "Vigabatrin was administered upon diagnosis, starting with a 50-mg/kg/day dose and increasing 50 mg/kg every 48 hours to reach a maximum dose of 200 mg/kg/day." | 2.41 | Vigabatrin as a first-choice drug in the treatment of West syndrome. ( Adi, J; Aldao, M; Caccia, P; Caraballo, R; Cersósimo, R; Corral, S; Di Blasi, MA; Fejerman, N; Grippo, J; Macat, MC; Martino, G; Martino, RH; Retamero, M, 2000) |
| " Corticotropin (adrenocorticotropic hormone) or corticosteroids have been the gold standard treatment for the last 40 years, but there is little agreement on the best agent to use, or the dosage and duration of the treatment." | 2.41 | A risk-benefit assessment of treatments for infantile spasms. ( Nabbout, R, 2001) |
| "Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter gamma-amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA-transaminase." | 2.40 | Vigabatrin. ( French, JA, 1999) |
| "Vigabatrin has been used as both add-on, and monotherapy in the treatment of spasms." | 2.39 | Vigabatrin in the management of generalized seizures in children. ( Appleton, RE, 1995) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Data from published research were extracted and evaluated according to study design, sample size, dosing regimen, outcome measures, and treatment efficacy and safety." | 2.39 | Treatment of infantile spasms. ( Casto, DT; Haines, ST, 1994) |
| "Aicardi syndrome is a neurodevelopmental disorder characterized by a triad of partial or complete agenesis of the corpus callosum, infantile spasms, and pathognomonic chorioretinal lacunae." | 1.91 | A case of Aicardi syndrome associated with duplication event of Xp22 including ( Ashit Parikh, A; Baldwin, G; Bodamer, OA; Gonzalez, E; Hoyek, S; Patel, NA; Yavuz Saricay, L, 2023) |
| " Twenty-three of the 25 VABAM cases have a peak dosage of VGB between 50 and 150 mg/kg/day." | 1.72 | Risk of vigabatrin-associated brain abnormalities on MRI: A retrospective and controlled study. ( Gao, J; Han, F; He, W; Liu, K; Luo, XM; Shi, XY; Wan, L; Wang, J; Wang, QH; Wang, YY; Xu, Y; Yang, G; Yang, XY; Zou, LP, 2022) |
| "Epileptic spasms were asymmetric in three patients and unilateral in two." | 1.72 | Status of epileptic spasms: A study of 21 children. ( Buompadre, C; Caraballo, R; Chacón, S; Fasulo, L; Gallo, A; Reyes, G; Semprino, M, 2022) |
| "Report a series of children with West syndrome (WS) treated with vigabatrin (VGB) who developed characteristic MRI alterations." | 1.72 | Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome. ( Calvo, A; Caraballo, RH; Crespo, A; Fassulo, L; Gallo, A; Pociecha, J; Princich, J; Reyes Valenzuela, G; Rugilo, C; Semprino, M, 2022) |
| "Individuals without hypsarrhythmia on the pretreatment EEG (i." | 1.72 | Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. ( Baumer, FM; Bhalla, S; Bhatia, S; Harini, C; Hussain, SA; Joshi, C; Keator, CG; Liu, S; Mytinger, JR; Samanta, D; Shellhaas, R; Singh, RK; Yozawitz, EG; Yuskaitis, CJ; Zhang, B, 2022) |
| "Prednisolone was generally well tolerated." | 1.72 | Treatment with High-Dose Prednisolone in Vigabatrin-Refractory Infantile Spasms. ( Al-Shehhi, W; Boyd, J; Chau, V; Donner, E; Go, C; Jain, P; Sharma, R; Snead, C, 2022) |
| "It has been known that West syndrome (WS) patients with an unknown etiology have better clinical outcomes than patients with an identified etiology of any kind." | 1.62 | Disparate treatment outcomes according to presence of pathogenic mutations in West syndrome. ( Choi, HS; Choi, JR; Kang, HC; Kim, HD; Kim, SH; Ko, A; Lee, JS; Lee, ST, 2021) |
| "However, West syndrome has not been previously well described as a consequence." | 1.62 | West Syndrome in Children With Congenital Zika Virus Infection. ( Bustamante Amador, J; García Boyano, M; García-Segovia, R; Miño-León, G, 2021) |
| "There are three recommended first-line treatments for infantile spasms, adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin, though non-standard treatments such as topiramate are sometimes selected." | 1.62 | Medication selection, health services outcomes, and cost trajectories for Medicaid beneficiaries with infantile spasms. ( Grinspan, ZM; Knupp, KG; Min, JY; Patel, AD; Shellhaas, RA; Zhang, M, 2021) |
| "Topiramate was used as an adjunct in 38 children who failed to hormonal therapy and/or vigabatrin and as initial monotherapy in one case." | 1.56 | Topiramate as an Adjunct in the Management of West Syndrome. ( Nadig, PL; Sahu, JK; Saini, A; Sankhyan, N; Suthar, R, 2020) |
| "Vigabatrin is an antiepileptic drug indicated as monotherapy in infantile spasms." | 1.51 | Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data. ( Bienayme, H; Chiron, C; Duhamel, P; Dulac, O; Jullien, V; Nabbout, R; Ounissi, M; Pons, G; Rodrigues, C, 2019) |
| "In five cases, tonic seizures preceded spasms at a median age of 6 weeks." | 1.51 | New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. ( Bienvenu, T; Chikvinidze, G; Dulac, O; Epitashvili, N; Gataullina, S; Melikishvili, G; Tabatadze, N, 2019) |
| "Relapse was relatively common among all subgroups." | 1.51 | Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol. ( Alayari, A; Eliyan, Y; Heesch, J; Hussain, SA; Rajaraman, RR; Sankar, R, 2019) |
| "Vigabatrin was approved for the treatment of infantile spasms by the US Food and Drug Administration, but not in Japan at the time of initiating this clinical study because of concerns about irreversible peripheral visual field defects (VFDs)." | 1.48 | Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study. ( Ohtsuka, Y, 2018) |
| "The prednisolone dose was increased to 60 mg/day if spasms were still present or the BASED score was ≥3 on day 21." | 1.48 | Vigabatrin and high-dose prednisolone therapy for patients with West syndrome. ( Chung, HJ; Kang, HC; Kim, HD; Kim, SH; Ko, A; Lee, JS; Youn, SE, 2018) |
| " For each patient we recorded dates of infantile spasms onset, response to vigabatrin, relapse (if any), and quantified duration and dosage of vigabatrin after response." | 1.48 | High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. ( Bebin, EM; Goyal, M; Hussain, SA; Krueger, DA; Northrup, H; Peters, JM; Sahin, M; Schmid, E; Wu, JY, 2018) |
| "Treatment choice and categorization of hypsarrhythmia were determined clinically at each site." | 1.46 | The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium. ( Bluvstein, JS; Chu, CJ; Demarest, ST; Gaillard, WD; Grinspan, Z; Hussain, SA; Joshi, S; Keator, C; Knupp, KG; Loddenkemper, T; Mohamed, IS; Nickels, KC; Patel, AD; Sánchez Fernández, I; Saneto, RP; Shellhaas, RA; Singh, RK; Stack, CV; Stafstrom, CE; Wirrell, E; Wusthoff, CJ; Yozawitz, E, 2017) |
| " Removal of this potential adverse effect with adjuvant intervention(s) would represent a significant advance in epilepsy therapeutics." | 1.46 | Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity? ( Ainslie, GR; Gibson, KM; Pearl, PL; Vogel, KR, 2017) |
| "Vigabatrin (VGB) is a first-line drug for the treatment of infantile spasms." | 1.46 | [Reversible alterations in the neuroimages associated with vigabatrine treatment in infants with epileptic spasms]. ( Fernandez-Garcia, MA; Garcia-Esparza, E; Garcia-Penas, JJ; Gomez-Martin, H; Perez-Sebastian, I; Sirvent-Cerda, S, 2017) |
| " Risk of asymptomatic VABAM was dose-dependent, as peak (but not cumulative) VGB dosage was strongly associated with asymptomatic VABAM (p = 0." | 1.46 | Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. ( Hussain, SA; Li, M; Salamon, N; Sankar, R; Schwarz, MD; Tsao, J; Wu, JY; Zhou, R, 2017) |
| "2) months, the median peak dosage was 141." | 1.43 | A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. ( Hussain, SA; Li, M; Sankar, R; Schwarz, MD; Tsao, J; Wu, JY; Wu, YW; Zhou, R, 2016) |
| "Vigabatrin (Sabril®) is an antiepileptic drug (AED) currently indicated in the US as a monotherapy for patients 1month to 2years of age with infantile spasms (IS) and as adjunctive therapy for patients ≥10years of age with refractory complex partial seizures (rCPS) whose seizures have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss." | 1.43 | Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. ( Dribinsky, Y; Faught, E; Foroozan, R; Isojarvi, J; Lee, D; Othman, F; Pellock, JM; Sergott, RC; Shields, WD; Torri, S; Ziemann, A, 2016) |
| "Time to relapse was not affected by treatment with ZNS or TPM." | 1.43 | Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit. ( Alayari, A; Anderson, K; Hussain, SA; Lay, J; Rajaraman, RR; Sankar, R, 2016) |
| "Epileptic spasms without hypsarrhythmia have been described in some series of patients, occurring either in infancy or childhood." | 1.42 | Epileptic spasms without hypsarrhythmia in infancy and childhood: tonic spasms as a seizure type. ( Carvalho, KC; Corso, JT; Ferrari-Marinho, T; Guaranha, MS; Marchi, LR; Naves, PV; Ramirez, MD; Seraphim, EA; Yacubian, EM, 2015) |
| "In all animals, hypsarrhythmia was abolished by the last treatment day." | 1.42 | Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms. ( Ballester-Rosado, C; Frost, JD; Hrachovy, RA; Le, JT; Lee, CL; Swann, JW, 2015) |
| "Valproic acid was prescribed most frequently as first and second treatment, followed by vigabatrin." | 1.42 | Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. ( Bindels-de Heus, K; de Wit, MC; Moll, HA; Overwater, IE; Rietman, AB; Ten Hoopen, LW; Vergouwe, Y, 2015) |
| "Vigabatrin is an antiepileptic drug used for treatment of infantile spasms." | 1.42 | Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms. ( Schonstedt, V; Silva, C; Stecher, X; Venegas, V, 2015) |
| "Vigabatrin (VGB), a treatment for the childhood epilepsy, infantile spasms (IS), is implicated in visual field constriction." | 1.40 | Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort. ( Dragas, R; Westall, C; Wright, T, 2014) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 1.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "The current treatment guidelines for treatment of infantile spasms is ambiguous regarding individuals with known etiology and is backed by limited evidence." | 1.40 | Practice experience in the treatment of infantile spasms at a tertiary care center. ( Sogawa, Y; Thodeson, D, 2014) |
| " There was neither effect of age of initiation of VGB treatment nor sex of the child on survival statistics and no significant effect of cumulative dosage on the occurrence of VGB-RD." | 1.40 | Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. ( Buncic, JR; Cortese, F; Kumarappah, A; Snead, OC; Westall, CA; Wright, T, 2014) |
| "Vigabatrin was effective for refractory childhood partial-onset epilepsy, and was not associated with symptomatic vision loss." | 1.38 | Vigabatrin for childhood partial-onset epilepsies. ( Agricola, K; Fordyce, S; Franz, DN; Greiner, HM; Krueger, DA; Lynch, ER; Tudor, C, 2012) |
| "Low-dose ACTH should be considered for treatment of infantile spasms." | 1.38 | Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. ( Adams-Webber, T; Ashwal, S; Go, CY; Mackay, MT; Snead, OC; Stephens, D; Weiss, SK, 2012) |
| "To define the profile of West syndrome in our environment by taking into account its aetiology, semiology, response to different therapeutic options and the appearance of side effects, as well as to establish prognostic factors that determine its course." | 1.37 | [West syndrome: aetiology, therapeutic options, clinical course and prognostic factors]. ( Arce-Portillo, E; Blanco-Martinez, B; Candau Fernandez-Mensaque, R; Madruga-Garrido, M; Munoz-Cabello, B; Rufo-Campos, M; Ruiz-Del Portal, L, 2011) |
| "Aicardi syndrome is a rare neurodevelopmental disorder characterized by corpus callosum agenesis, chorioretinal lacunae and early-onset infantile spasms." | 1.37 | [Aicardi syndrome associated with severe congenital ptosis]. ( Ben Mansour, L; Chabchoub, I; Daoued, E; Hachicha, M; Kamoun, F; Kamoun, T; Kmiha, S; Mnif, Z, 2011) |
| "Angelman syndrome is a rare genetic disorder scarcely diagnosed before the age of two years." | 1.37 | Angelman syndrome and pseudo-hypsarrhythmia: a diagnostic pitfall. ( Convers, P; Darteyre, S; Lebrun, M; Mazzola, L; Ville, D, 2011) |
| "Early control of seizures has a crucial role in preventing subsequent epileptic encephalopathy, and in reducing the cognitive/behavioural consequences of seizures, but does not guarantee for a normal mental outcome in children with TSC." | 1.36 | Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; Moavero, R; Pinci, M, 2010) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 1.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "Infantile spasms are characterized by age-specific expression of epileptic spasms and hypsarrhythmia and often result in significant cognitive impairment." | 1.36 | A model of symptomatic infantile spasms syndrome. ( Betancourth, D; Chudomelova, L; Galanopoulou, AS; Moshé, SL; Raffo, E; Scantlebury, MH, 2010) |
| " Affected versus unaffected patients, respectively, had a median age of 11 months versus 5 years, therapy duration 3 months versus 12 months, and dosage 170 mg/kg/day versus 87 mg/kg/day." | 1.35 | Cerebral MRI abnormalities associated with vigabatrin therapy. ( Conry, JA; de Menezes, MS; Elling, NJ; Ferri, R; Gaillard, WD; Gilles, E; Goodkin, HP; Heffron, A; Kadom, N; McCarter, R; McClintock, WM; Molloy-Wells, E; Pearl, PL; Saneto, RP; Trzcinski, S; Vezina, LG, 2009) |
| "Vigabatrin used to treat infantile spasms (IS) has been associated with transient magnetic resonance imaging (MRI) abnormalities." | 1.35 | Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. ( Bebin, M; Carmant, L; Chiron, C; Collins, SD; Conry, JA; Donald Shields, W; Elterman, RD; Frost, M; Paolicchi, JM; Thiele, EA; Wheless, JW; Zupanc, ML, 2009) |
| "Children with Down syndrome are highly susceptible to infantile spasms." | 1.35 | Infantile spasms and Down syndrome: a new animal model. ( Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y, 2009) |
| "Vigabatrin was started at a mean age of 7." | 1.35 | Visual fields at school-age in children treated with vigabatrin in infancy. ( Gaily, E; Jonsson, H; Lappi, M, 2009) |
| "Short-term outcomes for seizure cessation and electroencephalography normalization were identical between the groups." | 1.35 | Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. ( Ben-Zeev, B; Cohen-Sadan, S; Eidlitz, T; Goldberg-Stern, H; Kivity, S; Kramer, U; Lahat, E; Nevo, Y; Sahar, E; Zeharia, A, 2009) |
| "Epileptic seizures can be difficult to recognize in infancy and childhood because the semeiology can be misleading." | 1.35 | [Epileptic seizures in childhood: from seizure type to diagnosis]. ( Chabrol, B; Hugonencq, C; Mancini, J; Milh, M; Ticus, I; Villeneuve, N, 2008) |
| "Vigabatrin has proved to be effective against infantile spasms due to TSC." | 1.35 | Management of epilepsy in tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; D'Argenzio, L, 2008) |
| " The effects of the following factors on contrast sensitivity and visual acuity were examined: type of seizure (infantile spasms versus other), ERG result, duration of vigabatrin therapy, cumulative dosage of vigabatrin, and other seizure medications (other versus no other medication)." | 1.33 | Reduced visual function associated with infantile spasms in children on vigabatrin therapy. ( Buncic, JR; Hammoudi, DS; Lee, SS; Logan, WJ; Madison, A; Mirabella, G; Snead, OC; Westall, CA, 2005) |
| "Three infants affected with symptomatic West syndrome (WS), unresponsive to gamma-vinyl-GABA and to ACTH (first line drugs for WS), were rapidly cured with very small doses of lamotrigine (LTG)." | 1.31 | Low-dose lamotrigine in West syndrome. ( Cianchetti, C; Coppola, G; Pascotto, A; Pruna, D, 2002) |
| "Vigabatrin is an effective, well-tolerated treatment for infantile spasms." | 1.31 | Vigabatrin for infantile spasms. ( Mitchell, WG; Shah, NS, 2002) |
| "Vigabatrin (VGB) is a new-generation anticonvulsant used in the treatment of partial seizures and West syndrome." | 1.31 | Acute encephalopathy associated with vigabatrin in a six-month-old girl. ( Haas-Lude, K; Krägeloh-Mann, I; Niemann, G; Riethmüller, J; Wolff, M, 2000) |
| "Infantile spasms are typical crisis found in the childhood being a serious pathology with an obscure prognosis." | 1.31 | [Infantile spasms: experience in 13 cases]. ( Fonseca, LF; Oliveira, AL, 2000) |
| "Vigabatrin was well tolerated and only 2 patients developed somnolence and irritability." | 1.31 | The use of vigabatrin in infantile spasms in Asian children. ( Low, PS; Ong, HT; Tay, SK, 2001) |
| "To study the clinical pattern of West syndrome (WS) in a university based hospital." | 1.31 | West syndrome--The University of Hong Kong experience (1970-2000). ( Wong, V, 2001) |
| "EEG showed typical hypsarrhythmia in 8 cases, asymmetrical hypsarrhythmia in 1 case and modified hypsarrhythmia in another case." | 1.30 | [West's syndrome in patients with cerebral paralysis and periventricular leukomalacia: a good response to treatment]. ( Caraballo, R; Cersósimo, R; Fejerman, N; Intruvini, S; Pociecha, J, 1997) |
| "Vigabatrin (VGB) was specifically synthesized to enhance inhibitory GABAergic transmission by elevating GABA levels via irreversible inhibition of GABA transaminase." | 1.30 | [Monotherapy with vigabatrin in the treatment of West's syndrome]. ( Castro, E; Ocaña, O; Rufo, M; Santiago, C, 1997) |
| " Four of the six partial clinical responders had deterioration of spasms with additional VGB dosage increases." | 1.30 | Vigabatrin in the treatment of infantile spasms. ( Koo, B, 1999) |
| "ACTH is the standard treatment for infantile spasms (IS) in North America." | 1.30 | ACTH versus vigabatrin therapy in infantile spasms: a retrospective study. ( Carmant, L; Cossette, P; Riviello, JJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (13.40) | 18.2507 |
| 2000's | 80 (27.49) | 29.6817 |
| 2010's | 116 (39.86) | 24.3611 |
| 2020's | 56 (19.24) | 2.80 |
| Authors | Studies |
|---|---|
| Golec, W | 1 |
| Sołowiej, E | 1 |
| Strzelecka, J | 1 |
| Jurkiewicz, E | 2 |
| Jóźwiak, S | 3 |
| Xu, Y | 1 |
| Wan, L | 1 |
| He, W | 1 |
| Wang, YY | 1 |
| Wang, QH | 1 |
| Luo, XM | 1 |
| Liu, K | 1 |
| Yang, XY | 1 |
| Wang, J | 2 |
| Shi, XY | 1 |
| Yang, G | 1 |
| Han, F | 1 |
| Gao, J | 1 |
| Zou, LP | 1 |
| Caraballo, R | 4 |
| Semprino, M | 2 |
| Fasulo, L | 2 |
| Reyes, G | 1 |
| Chacón, S | 1 |
| Gallo, A | 2 |
| Buompadre, C | 1 |
| Saleh, DA | 1 |
| Hassan, A | 1 |
| Alrifai, MT | 1 |
| Al-Rumayyan, AR | 1 |
| Al-Tuwaijri, WA | 1 |
| Baarmah, DM | 1 |
| Asiri, SA | 1 |
| Bali, AH | 1 |
| Alsadhan, MA | 1 |
| Alsugheir, SH | 1 |
| Harvey, S | 1 |
| Allen, NM | 1 |
| King, MD | 1 |
| Lynch, B | 1 |
| Lynch, SA | 1 |
| O'Regan, M | 1 |
| O'Rourke, D | 1 |
| Shahwan, A | 1 |
| Webb, D | 1 |
| Gorman, KM | 1 |
| Reyes Valenzuela, G | 1 |
| Crespo, A | 1 |
| Princich, J | 1 |
| Fassulo, L | 1 |
| Rugilo, C | 1 |
| Pociecha, J | 2 |
| Calvo, A | 1 |
| Caraballo, RH | 1 |
| Barrett, KT | 1 |
| Choudhary, A | 1 |
| Charkhand, B | 1 |
| Scantlebury, MH | 4 |
| Baumer, FM | 3 |
| Mytinger, JR | 8 |
| Neville, K | 1 |
| Briscoe Abath, C | 1 |
| Gutierrez, CA | 1 |
| Numis, AL | 1 |
| Harini, C | 7 |
| He, Z | 1 |
| Hussain, SA | 12 |
| Berg, AT | 3 |
| Chu, CJ | 2 |
| Gaillard, WD | 6 |
| Loddenkemper, T | 5 |
| Pasupuleti, A | 2 |
| Samanta, D | 2 |
| Singh, RK | 4 |
| Singhal, NS | 1 |
| Wusthoff, CJ | 2 |
| Wirrell, EC | 2 |
| Yozawitz, E | 2 |
| Knupp, KG | 8 |
| Shellhaas, RA | 6 |
| Grinspan, ZM | 4 |
| Ramantani, G | 1 |
| Bölsterli, BK | 2 |
| Alber, M | 1 |
| Klepper, J | 2 |
| Korinthenberg, R | 2 |
| Kurlemann, G | 2 |
| Tibussek, D | 2 |
| Wolff, M | 3 |
| Schmitt, B | 11 |
| Yuskaitis, CJ | 3 |
| Zhang, B | 3 |
| Liu, S | 1 |
| Yozawitz, EG | 2 |
| Keator, CG | 2 |
| Joshi, C | 1 |
| Bhatia, S | 1 |
| Bhalla, S | 2 |
| Shellhaas, R | 1 |
| Parker, W | 1 |
| Rust, SW | 1 |
| Ahrens, SM | 1 |
| Albert, DVF | 2 |
| Beatty, CW | 1 |
| Chrisman, J | 1 |
| Clark, DJ | 1 |
| Debs, A | 1 |
| Denney, D | 1 |
| Karn, M | 1 |
| Herbst, J | 1 |
| Ostendorf, AP | 2 |
| Taylor, MC | 1 |
| Twanow, JDE | 1 |
| Vidaurre, J | 2 |
| Patel, AD | 4 |
| Dzau, W | 1 |
| Cheng, S | 1 |
| Snell, P | 1 |
| Fahey, M | 1 |
| Scheffer, IE | 1 |
| Harvey, AS | 1 |
| Howell, KB | 1 |
| Strzelczyk, A | 1 |
| Schubert-Bast, S | 1 |
| Motobayashi, M | 3 |
| Munakata, S | 3 |
| Kitazawa, N | 3 |
| Fushimi, T | 3 |
| Murayama, K | 3 |
| Inaba, Y | 3 |
| Sakpichaisakul, K | 2 |
| Boonkrongsak, R | 2 |
| Lertbutsayanukul, P | 2 |
| Iemwimangsa, N | 2 |
| Klumsathian, S | 2 |
| Panthan, B | 2 |
| Trachoo, O | 2 |
| Kuchenbuch, M | 1 |
| Chiron, C | 11 |
| Milh, M | 2 |
| Sánchez Fernández, I | 2 |
| Amengual-Gual, M | 1 |
| Barcia Aguilar, C | 1 |
| Romeu, A | 1 |
| Sheikh, T | 1 |
| Torres, A | 1 |
| Chao, J | 1 |
| Jonas, R | 1 |
| Gaínza-Lein, M | 1 |
| Douglass, L | 1 |
| Osborne, JP | 14 |
| Edwards, SW | 12 |
| Alber, FD | 3 |
| Hancock, E | 14 |
| Johnson, AL | 10 |
| Kennedy, CR | 11 |
| Likeman, M | 5 |
| Lux, AL | 12 |
| Mackay, M | 5 |
| Mallick, A | 2 |
| Newton, RW | 11 |
| Nolan, M | 4 |
| Pressler, R | 4 |
| Rating, D | 5 |
| Verity, CM | 11 |
| O'Callaghan, FK | 1 |
| Riikonen, R | 11 |
| Yavuz Saricay, L | 1 |
| Hoyek, S | 1 |
| Ashit Parikh, A | 1 |
| Baldwin, G | 1 |
| Bodamer, OA | 1 |
| Gonzalez, E | 1 |
| Patel, NA | 1 |
| Xu, Z | 1 |
| Gong, P | 1 |
| Jiao, X | 1 |
| Niu, Y | 1 |
| Wu, Y | 2 |
| Zhang, Y | 1 |
| Chang, X | 1 |
| Yang, Z | 1 |
| Zhang, YY | 1 |
| Guo, HL | 1 |
| Hu, YH | 1 |
| Lu, XP | 1 |
| Wang, SS | 1 |
| Wu, CF | 1 |
| Chen, F | 1 |
| Olson, HE | 1 |
| Demarest, S | 1 |
| Pestana-Knight, E | 1 |
| Moosa, AN | 1 |
| Zhang, X | 1 |
| Pérez-Pérez, JR | 1 |
| Weisenberg, J | 1 |
| O'Connor Prange, E | 1 |
| Marsh, ED | 1 |
| Rajaraman, RR | 4 |
| Suter, B | 1 |
| Katyayan, A | 2 |
| Haviland, I | 1 |
| Daniels, C | 1 |
| Greene, C | 1 |
| DeLeo, M | 2 |
| Swanson, L | 1 |
| Love-Nichols, J | 1 |
| Benke, T | 1 |
| Poduri, A | 2 |
| Takacs, DS | 1 |
| Vanderslice, K | 1 |
| Riviello, JJ | 2 |
| Lal, P | 1 |
| Sahu, JK | 4 |
| Sampaio, LPB | 1 |
| Henriques-Souza, AMM | 1 |
| Silveira, MRMD | 1 |
| Seguti, L | 1 |
| Santos, MLSF | 1 |
| Montenegro, MA | 2 |
| Antoniuk, S | 1 |
| Manreza, MLG | 1 |
| Dietrich Alber, F | 1 |
| O'Callaghan, FJK | 2 |
| Madaan, P | 2 |
| Negi, S | 1 |
| Sharma, R | 2 |
| Kaur, A | 1 |
| Nadig, PL | 1 |
| Suthar, R | 1 |
| Saini, A | 1 |
| Sankhyan, N | 1 |
| McFarlane, MT | 1 |
| Wright, T | 4 |
| McCoy, B | 2 |
| Snead, OC | 12 |
| Westall, CA | 10 |
| Twanow, JD | 1 |
| Tan, Y | 1 |
| Brock, GN | 1 |
| Asilnejad, B | 1 |
| Heesch, J | 2 |
| Navarro, M | 1 |
| Ji, M | 1 |
| Shrey, DW | 3 |
| Sankar, R | 7 |
| Chern, CR | 1 |
| Chern, CJ | 1 |
| Velíšková, J | 2 |
| Velíšek, L | 2 |
| Préel, M | 1 |
| Møller, RS | 1 |
| Miranda, MJ | 1 |
| Hoei-Hansen, CE | 1 |
| Mir, A | 1 |
| Hadab, S | 1 |
| Sammak, M | 1 |
| Alhazmi, R | 1 |
| Housawi, Y | 1 |
| Bashir, S | 1 |
| Choudhury, P | 1 |
| Spaull, R | 1 |
| Amin, S | 1 |
| Mallick, AA | 3 |
| Patel, JS | 1 |
| O'Callaghan, F | 2 |
| Ciliberto, MA | 1 |
| Cohen, BH | 1 |
| Dlugos, DJ | 2 |
| Joshi, SM | 1 |
| McGoldrick, PE | 1 |
| Nickels, KC | 4 |
| Park, JT | 1 |
| Pomeroy, SL | 1 |
| Shahid, AM | 1 |
| Wolf, SM | 1 |
| Waugh, JL | 1 |
| Pearl, PL | 5 |
| Chopra, SS | 1 |
| Heinrich, B | 1 |
| Critelli, H | 1 |
| Huber, R | 1 |
| Fattinger, S | 1 |
| Kim, DD | 1 |
| Sharma, AK | 1 |
| Sharma, M | 1 |
| Andrade, A | 1 |
| Fortini, S | 1 |
| Valenzuela, GR | 1 |
| Sinha, R | 1 |
| Anand, V | 1 |
| Gupta, J | 1 |
| Singh, S | 1 |
| Gulati, S | 1 |
| Chand, P | 1 |
| Kumar, A | 1 |
| Linn, K | 1 |
| Mynak, ML | 1 |
| Poudel, P | 1 |
| Wanigasinghe, J | 1 |
| Skjei, K | 1 |
| Biswas, A | 1 |
| Yossofzai, O | 1 |
| Vincent, A | 1 |
| Go, C | 5 |
| Widjaja, E | 3 |
| Kotulska, K | 2 |
| Kwiatkowski, DJ | 1 |
| Curatolo, P | 4 |
| Weschke, B | 2 |
| Riney, K | 1 |
| Jansen, F | 1 |
| Feucht, M | 1 |
| Krsek, P | 1 |
| Nabbout, R | 6 |
| Jansen, AC | 1 |
| Wojdan, K | 1 |
| Sijko, K | 1 |
| Głowacka-Walas, J | 1 |
| Borkowska, J | 1 |
| Sadowski, K | 1 |
| Domańska-Pakieła, D | 2 |
| Moavero, R | 2 |
| Hertzberg, C | 1 |
| Hulshof, H | 1 |
| Scholl, T | 1 |
| Benova, B | 1 |
| Aronica, E | 1 |
| de Ridder, J | 1 |
| Lagae, L | 2 |
| Lotan, E | 1 |
| Bluvstein, J | 1 |
| Zan, E | 1 |
| Fusco, L | 1 |
| Serino, D | 1 |
| Santarone, ME | 1 |
| Libenson, MH | 1 |
| Yang, E | 1 |
| Mysak, K | 1 |
| Marti, C | 1 |
| Peters, JM | 2 |
| Bergin, AM | 1 |
| Prabhu, SP | 2 |
| Datta, AN | 2 |
| Crawford, J | 1 |
| Wong, PKH | 1 |
| Bashiri, FA | 1 |
| Al-Sehemi, MA | 1 |
| Hamad, MH | 1 |
| Alshammari, NR | 1 |
| Aljumah, MA | 1 |
| Kentab, A | 1 |
| Salih, MA | 1 |
| Choi, HS | 1 |
| Ko, A | 2 |
| Kim, SH | 2 |
| Lee, ST | 1 |
| Choi, JR | 1 |
| Lee, JS | 2 |
| Kim, HD | 2 |
| Kang, HC | 2 |
| Al-Shehhi, W | 1 |
| Chau, V | 2 |
| Boyd, J | 4 |
| Snead, C | 2 |
| Donner, E | 1 |
| Jain, P | 2 |
| Bustamante Amador, J | 1 |
| García-Segovia, R | 1 |
| García Boyano, M | 1 |
| Miño-León, G | 1 |
| Min, JY | 1 |
| Zhang, M | 1 |
| Desnous, B | 1 |
| Lenoir, M | 1 |
| Bitton, JY | 1 |
| Arbour, M | 1 |
| Villeneuve, N | 3 |
| Whiting, S | 1 |
| Mohammed, I | 1 |
| Bello-Espinosa, L | 1 |
| Ronen, GM | 1 |
| Lortie, A | 2 |
| Birca, A | 1 |
| Fosi, T | 1 |
| Werner, K | 1 |
| Boyd, SG | 1 |
| De Haan, M | 1 |
| Scott, RC | 2 |
| Neville, BG | 1 |
| D'Alonzo, R | 1 |
| Rigante, D | 1 |
| Mencaroni, E | 1 |
| Esposito, S | 1 |
| Demarest, ST | 1 |
| Keator, C | 1 |
| Saneto, RP | 2 |
| Wirrell, E | 3 |
| Grinspan, Z | 2 |
| Joshi, S | 3 |
| Mohamed, IS | 1 |
| Stafstrom, CE | 1 |
| Stack, CV | 1 |
| Bluvstein, JS | 1 |
| Lay, J | 2 |
| Cheng, E | 1 |
| Weng, J | 1 |
| Baca, CB | 1 |
| Ohtsuka, Y | 1 |
| Goldstein, R | 1 |
| Atkinson, RM | 1 |
| Armstrong, D | 1 |
| Kinney, H | 1 |
| Trindade, RAR | 1 |
| Wainstein, B | 1 |
| Campos, LG | 1 |
| Pérez, JA | 1 |
| Bianchin, MM | 1 |
| Vedolin, LM | 1 |
| Duarte, JÁ | 1 |
| Kelley, SA | 1 |
| Youn, SE | 1 |
| Chung, HJ | 1 |
| Suzuki-Muromoto,, S | 1 |
| Uematsu, M | 1 |
| Sato, H | 1 |
| Numata-Uematsu, Y | 1 |
| Nakayama, T | 1 |
| Kiluchi, A | 1 |
| Kobayashi, T | 1 |
| Hino-Fukuyo, N | 1 |
| Kure, S | 1 |
| Kim McManus, O | 1 |
| Rajaraman, R | 1 |
| Ombao, H | 1 |
| Lopour, BA | 1 |
| Ounissi, M | 1 |
| Rodrigues, C | 1 |
| Bienayme, H | 1 |
| Duhamel, P | 1 |
| Pons, G | 1 |
| Dulac, O | 14 |
| Jullien, V | 1 |
| Zuberi, SM | 1 |
| Cortina Borja, M | 1 |
| Mackay, MT | 3 |
| Schmid, E | 1 |
| Goyal, M | 1 |
| Bebin, EM | 1 |
| Northrup, H | 1 |
| Sahin, M | 1 |
| Krueger, DA | 2 |
| Wu, JY | 3 |
| Melikishvili, G | 1 |
| Epitashvili, N | 1 |
| Tabatadze, N | 1 |
| Chikvinidze, G | 1 |
| Bienvenu, T | 1 |
| Gataullina, S | 1 |
| Chin, EM | 1 |
| Cohen, JS | 1 |
| Harris, J | 1 |
| Eliyan, Y | 1 |
| Alayari, A | 2 |
| Shumiloff, NA | 1 |
| Lam, WM | 1 |
| Manasco, KB | 1 |
| Hancock, EC | 1 |
| Fong, CY | 1 |
| Hemingway, C | 1 |
| Kneen, R | 1 |
| Mordekar, SR | 1 |
| Murugan, V | 1 |
| Pike, M | 1 |
| Quinn, M | 1 |
| Spinty, S | 1 |
| Vassallo, G | 1 |
| Whitney, A | 1 |
| O'Callaghan, FJ | 7 |
| Lee, J | 1 |
| Lee, JH | 1 |
| Yu, HJ | 1 |
| Lee, M | 1 |
| Oguni, H | 1 |
| Sugai, K | 1 |
| Romaniello, R | 1 |
| Zucca, C | 1 |
| Tenderini, E | 1 |
| Arrigoni, F | 1 |
| Ragona, F | 1 |
| Zorzi, G | 1 |
| Bassi, MT | 1 |
| Borgatti, R | 1 |
| Hernández Vega, Y | 1 |
| Kaliakatsos, M | 1 |
| U-King-Im, JM | 1 |
| Lascelles, K | 1 |
| Lim, M | 1 |
| Jones, K | 2 |
| Dragas, R | 1 |
| Westall, C | 1 |
| Rener-Primec, Z | 1 |
| Carmant, L | 6 |
| Dorofeeva, M | 1 |
| Hollody, K | 1 |
| Szabo, I | 1 |
| Krajnc, BS | 1 |
| Wohlrab, G | 6 |
| Sorri, I | 1 |
| Nielsen, JC | 1 |
| Kowalski, KG | 1 |
| Karim, A | 1 |
| Patel, M | 1 |
| Wesche, DL | 1 |
| Tolbert, D | 1 |
| Thodeson, D | 1 |
| Sogawa, Y | 1 |
| Djuric, M | 2 |
| Kravljanac, R | 2 |
| Tadic, B | 2 |
| Mrlješ-Popovic, N | 2 |
| Appleton, RE | 8 |
| Cortese, F | 1 |
| Kumarappah, A | 1 |
| Buncic, JR | 6 |
| Marchi, LR | 1 |
| Seraphim, EA | 1 |
| Corso, JT | 1 |
| Naves, PV | 1 |
| Carvalho, KC | 1 |
| Ramirez, MD | 1 |
| Ferrari-Marinho, T | 1 |
| Guaranha, MS | 1 |
| Yacubian, EM | 1 |
| Frost, JD | 1 |
| Le, JT | 1 |
| Lee, CL | 1 |
| Ballester-Rosado, C | 1 |
| Hrachovy, RA | 1 |
| Swann, JW | 1 |
| Overwater, IE | 1 |
| Bindels-de Heus, K | 1 |
| Rietman, AB | 1 |
| Ten Hoopen, LW | 1 |
| Vergouwe, Y | 1 |
| Moll, HA | 1 |
| de Wit, MC | 1 |
| Elterman, RD | 4 |
| Shields, WD | 8 |
| Ochi, A | 1 |
| Puka, K | 1 |
| Akula, JD | 1 |
| Schonstedt, V | 1 |
| Stecher, X | 1 |
| Venegas, V | 1 |
| Silva, C | 1 |
| Bugeme, M | 1 |
| Nawej, P | 1 |
| Mukuku, O | 1 |
| Coryell, J | 2 |
| Ryan, N | 2 |
| Leister, E | 2 |
| Hartman, AL | 2 |
| Kossoff, EH | 3 |
| Sullivan, J | 2 |
| Dlugos, D | 2 |
| Hamikawa, L | 2 |
| Millichap, J | 2 |
| Nordli, DR | 2 |
| Alwadhi, R | 1 |
| Kumar, V | 1 |
| Schwarz, MD | 2 |
| Li, M | 2 |
| Tsao, J | 2 |
| Zhou, R | 2 |
| Wu, YW | 1 |
| Pellock, JM | 8 |
| Faught, E | 1 |
| Foroozan, R | 1 |
| Sergott, RC | 3 |
| Ziemann, A | 1 |
| Lee, D | 1 |
| Dribinsky, Y | 1 |
| Torri, S | 1 |
| Othman, F | 1 |
| Isojarvi, J | 1 |
| Anderson, K | 1 |
| Iyer, A | 1 |
| Appleton, R | 2 |
| Juarez-Colunga, E | 1 |
| Hatori, T | 1 |
| Sugiyama, Y | 1 |
| Yamashita, S | 1 |
| Hirakubo, Y | 1 |
| Nonaka, K | 1 |
| Ichihashi, K | 1 |
| Vogel, KR | 1 |
| Ainslie, GR | 1 |
| Gibson, KM | 1 |
| Sun, LR | 1 |
| Bosemani, T | 1 |
| Smith-Hicks, CL | 1 |
| Fernandez-Garcia, MA | 1 |
| Garcia-Penas, JJ | 1 |
| Gomez-Martin, H | 1 |
| Perez-Sebastian, I | 1 |
| Garcia-Esparza, E | 1 |
| Sirvent-Cerda, S | 1 |
| Salamon, N | 1 |
| Vezina, LG | 1 |
| McCarter, R | 1 |
| Molloy-Wells, E | 1 |
| Heffron, A | 1 |
| Trzcinski, S | 1 |
| McClintock, WM | 1 |
| Conry, JA | 3 |
| Elling, NJ | 1 |
| Goodkin, HP | 1 |
| de Menezes, MS | 1 |
| Ferri, R | 1 |
| Gilles, E | 1 |
| Kadom, N | 1 |
| Muzykewicz, DA | 1 |
| Costello, DJ | 1 |
| Halpern, EF | 1 |
| Thiele, EA | 5 |
| Jaseja, H | 4 |
| Karvelas, G | 2 |
| Duy, PT | 1 |
| Cossette, P | 2 |
| Wheless, JW | 3 |
| Bebin, M | 1 |
| Frost, M | 1 |
| Paolicchi, JM | 1 |
| Donald Shields, W | 1 |
| Zupanc, ML | 1 |
| Collins, SD | 2 |
| Cortez, MA | 1 |
| Shen, L | 1 |
| Aleem, IS | 1 |
| Trepanier, CH | 1 |
| Sadeghnia, HR | 1 |
| Ashraf, A | 1 |
| Kanawaty, A | 1 |
| Liu, CC | 1 |
| Stewart, L | 1 |
| Gaily, E | 5 |
| Jonsson, H | 1 |
| Lappi, M | 1 |
| Willmore, LJ | 1 |
| Abelson, MB | 1 |
| Ben-Menachem, E | 2 |
| Durbin, S | 1 |
| Mirabella, G | 3 |
| Cohen-Sadan, S | 1 |
| Kramer, U | 1 |
| Ben-Zeev, B | 1 |
| Lahat, E | 1 |
| Sahar, E | 1 |
| Nevo, Y | 1 |
| Eidlitz, T | 1 |
| Zeharia, A | 1 |
| Kivity, S | 1 |
| Goldberg-Stern, H | 1 |
| Riikonen, RS | 2 |
| Bombardieri, R | 3 |
| Pinci, M | 1 |
| Cerminara, C | 2 |
| Leiba, H | 1 |
| Kästle, R | 1 |
| Ramelli, G | 1 |
| Schmitt-Mechelke, T | 1 |
| Landau, K | 2 |
| Cazorla, MR | 1 |
| Verdú, A | 1 |
| Montes, C | 1 |
| Ayuga, F | 1 |
| Thompson, CA | 1 |
| Horton, M | 1 |
| Rafay, M | 1 |
| Del Bigio, MR | 1 |
| Kubová, H | 1 |
| Mares, P | 1 |
| Galanopoulou, AS | 2 |
| Chudomelova, L | 2 |
| Raffo, E | 2 |
| Betancourth, D | 2 |
| Moshé, SL | 1 |
| Tolman, JA | 1 |
| Faulkner, MA | 1 |
| Ibrahim, S | 1 |
| Gulab, S | 1 |
| Ishaque, S | 1 |
| Saleem, T | 1 |
| Mikati, MA | 1 |
| Cornett, KM | 1 |
| Verhelst, H | 1 |
| Ceulemans, B | 1 |
| De Meirleir, L | 1 |
| Nassogne, MC | 1 |
| De Borchgrave, V | 1 |
| D'Hooghe, M | 1 |
| Foulon, M | 1 |
| Van Bogaert, P | 1 |
| Chugani, HT | 1 |
| Asano, E | 1 |
| Sood, S | 1 |
| Dracopoulos, A | 1 |
| Raybaud, C | 1 |
| Bittman, RM | 1 |
| Torri, SA | 1 |
| Sagar, SM | 1 |
| Darke, K | 2 |
| Hong, AM | 1 |
| Turner, Z | 1 |
| Hamdy, RF | 1 |
| Hrachovy, R | 1 |
| Shinnar, S | 2 |
| Baram, TZ | 3 |
| Bettis, D | 1 |
| Gibson, PA | 2 |
| Holmes, GL | 1 |
| Nordl, DR | 1 |
| O'Dell, C | 2 |
| Trevathan, E | 1 |
| Coppola, A | 1 |
| Besag, FM | 1 |
| Simao, GN | 1 |
| Zarei Mahmoodabadi, S | 1 |
| Bast, T | 1 |
| Dalla Bernardina, B | 1 |
| Neville, B | 1 |
| Fukuyama, Y | 1 |
| Thelle, T | 1 |
| Gammelgaard, L | 1 |
| Hansen, JK | 1 |
| Østergaard, JR | 1 |
| Navas-Sánchez, P | 1 |
| Martínez-Antón, J | 1 |
| Bauzano-Poley, E | 1 |
| Ando, N | 1 |
| Fujimoto, S | 1 |
| Ishikawa, T | 1 |
| Kobayashi, S | 1 |
| Hattori, A | 1 |
| Ito, T | 1 |
| Togari, H | 1 |
| Arce-Portillo, E | 1 |
| Rufo-Campos, M | 1 |
| Munoz-Cabello, B | 1 |
| Blanco-Martinez, B | 1 |
| Madruga-Garrido, M | 1 |
| Ruiz-Del Portal, L | 1 |
| Candau Fernandez-Mensaque, R | 1 |
| Mohamed, BP | 1 |
| Desai, N | 1 |
| Gutta, P | 1 |
| Patil, S | 1 |
| Pesaturo, KA | 1 |
| Spooner, LM | 1 |
| Belliveau, P | 1 |
| Chabchoub, I | 1 |
| Kamoun, F | 1 |
| Daoued, E | 1 |
| Ben Mansour, L | 1 |
| Kmiha, S | 1 |
| Kamoun, T | 1 |
| Mnif, Z | 1 |
| Hachicha, M | 1 |
| Chachua, T | 1 |
| Yum, MS | 2 |
| Darteyre, S | 1 |
| Mazzola, L | 1 |
| Convers, P | 1 |
| Lebrun, M | 1 |
| Ville, D | 1 |
| Brodie, SE | 1 |
| Plant, GT | 1 |
| Walker, SD | 1 |
| Kälviäinen, R | 1 |
| Good, WV | 1 |
| Silverman, RB | 1 |
| Greiner, HM | 1 |
| Lynch, ER | 1 |
| Fordyce, S | 1 |
| Agricola, K | 1 |
| Tudor, C | 1 |
| Franz, DN | 1 |
| Aguilera-Albesa, S | 1 |
| Poretti, A | 1 |
| Honnef, D | 1 |
| Aktas, M | 1 |
| Yoldi-Petri, ME | 1 |
| Huisman, TA | 1 |
| Häusler, M | 1 |
| Carvalho Neto, Ad | 1 |
| Coelho, LO | 1 |
| Ono, SE | 1 |
| Crippa, AC | 1 |
| Vendrame, M | 1 |
| Guilhoto, LM | 1 |
| Gregas, M | 1 |
| Bourgeois, BF | 1 |
| Kothare, SV | 1 |
| Go, CY | 1 |
| Weiss, SK | 3 |
| Stephens, D | 2 |
| Adams-Webber, T | 2 |
| Ashwal, S | 2 |
| Lee, EH | 1 |
| Ko, TS | 1 |
| Korff, CM | 1 |
| Vulliemoz, S | 1 |
| Picard, F | 1 |
| Fluss, J | 1 |
| Rosbeck, KL | 1 |
| Hardin, M | 1 |
| Whittemore, V | 1 |
| Hsieh, DT | 1 |
| Dill, P | 1 |
| Weber, P | 1 |
| Schneider, J | 1 |
| Cianchetti, C | 1 |
| Pruna, D | 1 |
| Coppola, G | 4 |
| Pascotto, A | 2 |
| Mitchell, WG | 1 |
| Shah, NS | 1 |
| Kankirawatana, P | 1 |
| Raksadawan, N | 1 |
| Balangkura, K | 1 |
| Askalan, R | 1 |
| Brian, J | 1 |
| Otsubo, H | 1 |
| McDermott, C | 1 |
| Bryson, S | 1 |
| Roberts, W | 1 |
| Weiss, S | 2 |
| Capovilla, G | 1 |
| Beccaria, F | 2 |
| Montagnini, A | 2 |
| Cusmai, R | 1 |
| Franzoni, E | 1 |
| Moscano, F | 1 |
| Carotenuto, M | 1 |
| Gobbi, G | 1 |
| Seri, S | 1 |
| Vigevano, F | 2 |
| Osborne, J | 1 |
| Milner, P | 2 |
| Morong, S | 3 |
| Nobile, R | 2 |
| Logan, WJ | 4 |
| Panton, CM | 2 |
| Abdolell, M | 2 |
| Rotta, NT | 1 |
| da Silva, AR | 1 |
| Ohlweiler, L | 1 |
| Riesgo, R | 1 |
| Ballaban-Gill, K | 1 |
| Duchowny, M | 1 |
| Hirtz, D | 1 |
| Wyllie, E | 1 |
| Buoni, S | 2 |
| Zannolli, R | 2 |
| Strambi, M | 1 |
| Fois, A | 2 |
| Jacob, P | 1 |
| Hammoudi, DS | 1 |
| Lee, SS | 1 |
| Madison, A | 1 |
| Cvitanović-Sojat, L | 1 |
| Gjergja, R | 1 |
| Sabol, Z | 1 |
| Hajnzić, TF | 1 |
| Sojat, T | 1 |
| Moraes, MH | 1 |
| Franzon, RC | 1 |
| Avila, JO | 1 |
| Guerreiro, MM | 1 |
| Rasmussen, M | 2 |
| Sandvig, I | 2 |
| Nustad, A | 2 |
| Skjeldal, OH | 2 |
| Hansen, LK | 1 |
| Rasmussen, NH | 1 |
| Waterham, H | 1 |
| Wanders, R | 1 |
| Kröll-Seger, J | 1 |
| Kaminska, A | 1 |
| Moutard, ML | 1 |
| de Saint-Martin, A | 1 |
| Guët, A | 1 |
| Henriques-Souza, AM | 1 |
| Ataide Junior, L | 1 |
| Laurentino, SG | 1 |
| Verrotti, A | 1 |
| Manco, R | 1 |
| Coppola, GG | 1 |
| Mingione, S | 1 |
| Chiarelli, F | 1 |
| Iannetti, P | 1 |
| Parisi, P | 1 |
| Kaczorowska, M | 1 |
| Dunin-Wasowicz, D | 1 |
| Kasprzyk-Obara, J | 1 |
| Kapusta, M | 1 |
| Milewska-Bobula, B | 1 |
| Auvichayapat, N | 1 |
| Tassniyom, S | 1 |
| Treerotphon, S | 1 |
| Auvichayapat, P | 1 |
| Visudhiphan, P | 2 |
| Desguerre, I | 1 |
| Ticus, I | 1 |
| Hugonencq, C | 1 |
| Mancini, J | 1 |
| Chabrol, B | 1 |
| D'Argenzio, L | 1 |
| Maheshwari, N | 1 |
| Zaiwalla, Z | 1 |
| McShane, MA | 1 |
| Camposano, SE | 1 |
| Major, P | 1 |
| Halpern, E | 1 |
| Baxter, PS | 1 |
| Gardner-Medwin, D | 1 |
| Barwick, DD | 1 |
| Ince, P | 1 |
| Livingston, J | 1 |
| Murdoch-Eaton, D | 1 |
| Vogt, H | 1 |
| Krämer, G | 1 |
| Haines, ST | 1 |
| Casto, DT | 1 |
| Montiel-Viesca, F | 1 |
| Boltshauser, E | 3 |
| Vles, JS | 1 |
| van der Heyden, AM | 1 |
| Ghijs, A | 1 |
| Troost, J | 1 |
| Backström, M | 1 |
| Eriksson, K | 1 |
| Koivikko, M | 1 |
| Aicardi, J | 1 |
| Mumford, JP | 3 |
| Dumas, C | 3 |
| Wood, S | 1 |
| López-Valdés, E | 1 |
| Hernández-Laín, A | 1 |
| Simón, R | 1 |
| Porta, J | 1 |
| Mateos, F | 1 |
| Jambaqué, I | 2 |
| Mumford, J | 3 |
| Kwong, L | 1 |
| Cersósimo, R | 2 |
| Intruvini, S | 1 |
| Fejerman, N | 2 |
| Rufo, M | 1 |
| Santiago, C | 1 |
| Castro, E | 1 |
| Ocaña, O | 1 |
| Terraciano, AM | 1 |
| Cilio, MR | 1 |
| Dooley, J | 1 |
| Gordon, K | 1 |
| Dooley, K | 1 |
| Siemes, H | 1 |
| Brandl, U | 1 |
| Spohr, HL | 1 |
| Völger, S | 1 |
| Soufflet, C | 1 |
| Plouin, P | 1 |
| Johnson, T | 1 |
| Lhatoo, SD | 1 |
| Sander, JW | 1 |
| Koo, B | 1 |
| Wasterlain, CG | 1 |
| Roubergue, A | 1 |
| Schlumberger, ME | 1 |
| Billette de Villemeur, T | 1 |
| Granström, ML | 2 |
| Liukkonen, E | 2 |
| Schriever, S | 1 |
| French, JA | 1 |
| Visudtibhan, A | 1 |
| Chiemchanya, S | 1 |
| Phusirimongkol, S | 1 |
| Peters, AC | 1 |
| Shaw, DE | 1 |
| Cohen, JA | 1 |
| Fisher, RS | 1 |
| Brigell, MG | 1 |
| Peyster, RG | 1 |
| Sze, G | 1 |
| Grippo, J | 1 |
| Corral, S | 1 |
| Martino, RH | 1 |
| Martino, G | 1 |
| Aldao, M | 1 |
| Caccia, P | 1 |
| Retamero, M | 1 |
| Macat, MC | 1 |
| Di Blasi, MA | 1 |
| Adi, J | 1 |
| Haas-Lude, K | 1 |
| Riethmüller, J | 1 |
| Niemann, G | 1 |
| Krägeloh-Mann, I | 1 |
| Fonseca, LF | 1 |
| Oliveira, AL | 1 |
| Antoniuk, SA | 1 |
| Bruck, I | 1 |
| Spessatto, A | 1 |
| Halick, SM | 1 |
| de Bruyn, LR | 1 |
| Meister, E | 1 |
| de Paola, D | 1 |
| Prasad, AN | 1 |
| Penney, S | 1 |
| Buckley, DJ | 1 |
| Tay, SK | 1 |
| Ong, HT | 1 |
| Low, PS | 1 |
| Paetau, R | 1 |
| Rekola, R | 1 |
| Mansfield, KA | 1 |
| Nakagawa, J | 1 |
| Hwang, YS | 1 |
| Young, C | 1 |
| Koul, R | 1 |
| Chacko, A | 1 |
| Cherian, E | 1 |
| Wong, V | 1 |
| Melki, I | 1 |
| Gerbaka, B | 1 |
| Akatcherian, C | 1 |
| Primec, ZR | 1 |
| Kopac, S | 1 |
| Neubauer, D | 1 |
| Gram, L | 1 |
| Sabers, A | 1 |
| Beaumont, D | 2 |
| Palacios, L | 2 |
| Pajot, N | 1 |
| Luna, D | 1 |
| Mondragon, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial[NCT04302116] | 250 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | |||
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| Decreasing Parental Stress and Costs While Improving Overall Satisfaction of Caregivers of Infants With Infantile Spasms on ACTH Therapy Utilizing Innovative Telemedicine Technology: A Randomized Study[NCT04086992] | 40 participants (Anticipated) | Interventional | 2019-10-10 | Recruiting | |||
| Effect of Neuro Developmental Therapy to Improve Postural Reactions and Motor Milestones in Infants With Down Syndrome[NCT04816409] | 20 participants (Actual) | Interventional | 2019-03-15 | Completed | |||
| ADRENL - ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children, Pilot Study[NCT03408405] | Phase 4 | 0 participants (Actual) | Interventional | 2018-06-30 | Withdrawn (stopped due to Withdrawal of funding from primary sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
61 reviews available for vigabatrin and Cryptogenic Infantile Spasms
| Article | Year |
|---|---|
Vigabatrin - new data on indications and safety in paediatric epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Spasms, Infantile; Tuberous Sclerosis; Vigabatrin | 2021 |
Animal Models in Epileptic Spasms and the Development of Novel Treatment Options.
Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Electroencephalography; Humans; Models, Anima | 2022 |
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Topics: Autism Spectrum Disorder; Bromides; Cannabidiol; Clobazam; Cognition; Ethosuximide; Everolimus; Felb | 2022 |
Overview of therapeutic options for epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Prognosis; Seizures; Spasms, | 2022 |
Biochemical mechanisms in pathogenesis of infantile epileptic spasm syndrome.
Topics: Anticonvulsants; Epilepsy; Glucocorticoids; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2023 |
Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis.
Topics: Anticonvulsants; Humans; Spasm; Spasms, Infantile; Syndrome; Vigabatrin | 2023 |
[Infantile spasms].
Topics: Anticonvulsants; Child; Electroencephalography; Humans; Infant; Magnetic Resonance Imaging; Spasms, | 2020 |
Infantile Spasms: Outcome in Clinical Studies.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anticonvulsants; Child; Child, Preschool; Glucocorti | 2020 |
Infantile Spasms and West Syndrome - A Clinician's Perspective.
Topics: Anticonvulsants; Humans; Infant; Risk Assessment; Spasms, Infantile; Vigabatrin | 2020 |
Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: Three cases and review of the literature.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain Diseases; Drug Therapy, Combination; Fatal Outco | 2020 |
Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis.
Topics: Anticonvulsants; Humans; Infant; Spasms, Infantile; Vigabatrin | 2020 |
Three different scenarios for epileptic spasms.
Topics: Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2020 |
West Syndrome: A Review and Guide for Paediatricians.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Clinical Trials as Topic; Ele | 2018 |
Infantile Spasms-Have We Made Progress?
Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Child; Child, Preschool; Combined Modality Th | 2018 |
Adrenocorticotropic hormone for the treatment of West Syndrome in children.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Child; Child, Preschool; Dose-Resp | 2013 |
Treatment of infantile spasms.
Topics: Anticonvulsants; Cosyntropin; Hormones; Humans; Infant; Prednisolone; Psychomotor Performance; Rando | 2013 |
[Current problems of treatment for infantile spasms].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Secondary Prevention; Spasms, Infantil | 2010 |
Recent advances in the pharmacotherapy of infantile spasms.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Anticonvulsants; Cognition Disorders; | 2014 |
Treatment of Infantile Spasms: Report of the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society for Neuropediatrics.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Diet, Ketogenic; Hormones; Hu | 2016 |
Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyridoxine; S | 2016 |
Justification of vigabatrin administration in West syndrome patients? Warranting a re-consideration for improvement in their quality of life.
Topics: Anticonvulsants; Humans; Infant; Quality of Life; Retinal Diseases; Spasms, Infantile; Treatment Out | 2009 |
Vigabatrin: 2008 update.
Topics: Adult; Anticonvulsants; Child; Cognition; Controlled Clinical Trials as Topic; Cross-Over Studies; D | 2009 |
Favourable prognostic factors with infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Developmental Disabilities; Electroencephalography; Hu | 2010 |
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
Topics: Adult; Animals; Anticonvulsants; Drug Approval; Epilepsy, Complex Partial; Humans; Infant; Middle Ag | 2009 |
Infantile spasms: a U.S. consensus report.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Consensus; Consensus Developm | 2010 |
Infantile spasms: a U.S. consensus report.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Consensus; Consensus Developm | 2010 |
Infantile spasms: a U.S. consensus report.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Consensus; Consensus Developm | 2010 |
Infantile spasms: a U.S. consensus report.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Consensus; Consensus Developm | 2010 |
Modeling new therapies for infantile spasms.
Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Disease Models, Animal; Humans; Infant; Mice; | 2010 |
Vigabatrin for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Clinical Trials as Topic; Electroenc | 2011 |
Mechanism of action of vigabatrin: correcting misperceptions.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticonvulsants; Drug Administration Schedule; Epilepsies, | 2011 |
Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing.
Topics: Anticonvulsants; Canada; Clinical Trials as Topic; Constipation; Europe; Feeding and Eating Disorder | 2011 |
Understanding and interpreting vision safety issues with vigabatrin therapy.
Topics: 4-Aminobutyrate Transaminase; Adult; Animals; Anticonvulsants; Causality; Comorbidity; Confounding F | 2011 |
Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
Topics: Adult; Anticonvulsants; Electroretinography; Epilepsies, Partial; GABA Agents; Humans; Infant; Spasm | 2011 |
Non-vision adverse events with vigabatrin therapy.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Animals; Anticonvulsants; Brain Diseases; Cognition | 2011 |
Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
Topics: Adult; Animals; Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Magnetic Resonance Imag | 2011 |
Vigabatrin monotherapy for infantile spasms.
Topics: Anticonvulsants; Brain; Diffusion Tensor Imaging; Humans; Infant; Randomized Controlled Trials as To | 2012 |
Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Continuity of Patient Care; Directive Counseling; Huma | 2012 |
Treatment of infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Psychomotor Performance; Randomized Controlled Trials as Topic; Spa | 2003 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2004 |
Pharmacologic treatment of the catastrophic epilepsies.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Epilepsy; Fructose; Humans; Infant; Isoxaz | 2004 |
Infantile spasms: therapy and outcome.
Topics: Adrenocorticotropic Hormone; Humans; Infant; Infant, Newborn; Prospective Studies; Randomized Contro | 2004 |
Managing epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Cognition Disorders; Diet Therapy; Electroencephalography; Epilepsy; Humans; | 2004 |
The latest on infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Spasms, Infantile; Steroids; Vigabatrin | 2005 |
[Infantile spasms].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Glucocorticoids; Humans; Infant, Newborn; Prognosis; S | 2005 |
[Treatment of infantile spasms].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Prognosis; Spasms, Infantile; Treatmen | 2006 |
Update of the medical treatment of West syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Glu | 2007 |
Current role of vigabatrin in infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Infant, Newborn; Spasms, Infantile; Vigabatrin | 2007 |
Vigabatrin in the management of generalized seizures in children.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Epileps | 1995 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
Treatment of infantile spasms.
Topics: 4-Aminobutyrate Transaminase; Adrenocorticotropic Hormone; Anticonvulsants; Benzodiazepines; gamma-A | 1994 |
Vigabatrin in newly diagnosed infantile spasms.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Infant, Newborn; Spasms, Infantile; Treatm | 1994 |
The role of vigabatrin in the management of infantile epileptic syndromes.
Topics: Aminocaproates; Anticonvulsants; Child, Preschool; Epilepsies, Partial; Epilepsy; Humans; Infant; Sp | 1993 |
Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Spasms, Infantile; Tuberous Sclerosis; Vig | 1999 |
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec | 1999 |
Vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Anticonvulsants; Brain Chemistry; Clinical Trials as Topic; Cognition; | 1999 |
The potential for vigabatrin-induced intramyelinic edema in humans.
Topics: Animals; Anticonvulsants; Brain; Brain Diseases; Clinical Trials as Topic; Dogs; Edema; Epilepsy; Ev | 2000 |
Vigabatrin as a first-choice drug in the treatment of West syndrome.
Topics: Anticonvulsants; Argentina; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration | 2000 |
Steroids or vigabatrin in the treatment of infantile spasms?
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Infant, Newborn; Spasms, Infantile; Tu | 2000 |
A risk-benefit assessment of treatments for infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Epilepsy; Humans; Immunoglobulins; Infant; Pyridoxine; | 2001 |
ACTH therapy of West syndrome: Finnish views.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Finland; Humans; Infant; Spasms, Infantile; Vigabatrin | 2001 |
Drug therapy for West's syndrome.
Topics: Anticonvulsants; Humans; Infant; Infant, Newborn; Lamotrigine; Spasms, Infantile; Steroids; Triazine | 2002 |
Treatment of infantile spasms: an evidence-based approach.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2002 |
Treatment of infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Psychomotor Performance; Randomized Controlled Trials as Topic; Spa | 2002 |
28 trials available for vigabatrin and Cryptogenic Infantile Spasms
| Article | Year |
|---|---|
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2021 |
Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial.
Topics: Cosyntropin; Drug Administration Schedule; Drug Therapy, Combination; Electroencephalography; Female | 2018 |
Response to treatment in a prospective national infantile spasms cohort.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Child, | 2016 |
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
Topics: Anticonvulsants; Cosyntropin; Drug Administration Schedule; Drug Therapy, Combination; Electroenceph | 2017 |
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
Topics: Anticonvulsants; Cosyntropin; Drug Administration Schedule; Drug Therapy, Combination; Electroenceph | 2017 |
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
Topics: Anticonvulsants; Cosyntropin; Drug Administration Schedule; Drug Therapy, Combination; Electroenceph | 2017 |
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
Topics: Anticonvulsants; Cosyntropin; Drug Administration Schedule; Drug Therapy, Combination; Electroenceph | 2017 |
Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Asphyxia Neonatorum; Cerebral Palsy; Developing Countr | 2010 |
Vigabatrin for the treatment of infantile spasms: final report of a randomized trial.
Topics: Anticonvulsants; Chi-Square Distribution; Child, Preschool; Electroencephalography; Female; Humans; | 2010 |
Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cosyntropin; Epidemiologic Methods; Glucocorti | 2010 |
The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study.
Topics: Age of Onset; Anticonvulsants; Child Development; Cosyntropin; Early Diagnosis; Humans; Infant; Infa | 2011 |
Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Autistic Disorder; Cognition Disorders; Electroencepha | 2003 |
Combined treatment with vigabatrin and topiramate in West syndrome.
Topics: Anticonvulsants; Brain; Child Development; Drug Therapy, Combination; Female; Follow-Up Studies; Fru | 2004 |
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents; Anticonvulsants; Child Development; Cosyntropin | 2005 |
Contrast sensitivity is reduced in children with infantile spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Cross-Sectional Studies; | 2007 |
Vigabatrin in infantile spasms--why add on?
Topics: Aminocaproates; Anticonvulsants; Humans; Infant; Recurrence; Spasms, Infantile; Vigabatrin | 1993 |
Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.
Topics: Age of Onset; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Drug Administrati | 1996 |
Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis.
Topics: Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Hydrocortisone; Infant; Infant, Newborn; M | 1997 |
Vigabatrin as first line therapy in infantile spasms: review of seven patients.
Topics: Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Infant; Male; Spasms, Infantile; Treatment | 1997 |
Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combinat | 1997 |
Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.
Topics: Adrenocorticotropic Hormone; Age of Onset; Anticonvulsants; Delayed-Action Preparations; Drug Admini | 1997 |
Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cerebral Cortex; Child, Preschool; Developmental Disab | 1998 |
Long-term follow-up study of vigabatrin in pretreated children with West syndrome.
Topics: Adrenocorticotropic Hormone; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child, Preschool | 1998 |
Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.
Topics: 4-Aminobutyrate Transaminase; Adrenocorticotropic Hormone; Anticonvulsants; Brain Diseases; Child; C | 1999 |
Visual field constriction is not limited to children treated with vigabatrin.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy, Co | 1999 |
Vigabatrin in infantile spasms: preliminary result.
Topics: Anticonvulsants; Electroencephalography; Female; Follow-Up Studies; Humans; Infant; Male; Remission | 1999 |
Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Electroencephalogr | 1999 |
[West syndrome: clinical and electroencephalographic follow up of 70 patients and response to its treatment with adrenocorticotropic hormone, prednisone, vigabatrin, nitrazepam and valproate].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anticonvulsants; Child; Child, Preschool; Electroenc | 2000 |
Infantile spasms: diagnosis and assessment of treatment response by video-EEG.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain; Carbamazepine; Clobazam; Electroenceph | 2001 |
Randomized trial of vigabatrin in patients with infantile spasms.
Topics: Anticonvulsants; Child, Preschool; Female; Humans; Infant; Male; Single-Blind Method; Spasms, Infant | 2001 |
Infantile spasms in Down syndrome: good response to a short course of vigabatrin.
Topics: Adolescent; Age of Onset; Anticonvulsants; Child; Comorbidity; Down Syndrome; Drug Administration Sc | 2001 |
202 other studies available for vigabatrin and Cryptogenic Infantile Spasms
| Article | Year |
|---|---|
Risk of vigabatrin-associated brain abnormalities on MRI: A retrospective and controlled study.
Topics: Anticonvulsants; Brain; Child; Humans; Magnetic Resonance Imaging; Retrospective Studies; Spasms, In | 2022 |
Status of epileptic spasms: A study of 21 children.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsy; Humans; Infant; Spasm; Spasms, Infantile; | 2022 |
Clinical profile, treatment modalities, and outcomes in patients with infantile spasms: A retrospective study from the United Arab of Emirates (UAE).
Topics: Anticonvulsants; Arabs; Child; Humans; Infant; Retrospective Studies; Spasms, Infantile; Treatment O | 2022 |
The response patterns of infantile spasms to treatments in 156 patients: Hormonal therapy with intravenous synthetic ACTH appears promising.
Topics: Administration, Intravenous; Anticonvulsants; Cosyntropin; Humans; Infant; Retrospective Studies; Sa | 2022 |
Response to treatment and outcomes of infantile spasms in Down syndrome.
Topics: Adult; Anticonvulsants; Child; Down Syndrome; Humans; Infant; Prednisolone; Seizures; Spasm; Spasms, | 2022 |
Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome.
Topics: Anticonvulsants; Brain; Brain Diseases; Child; Humans; Infant; Magnetic Resonance Imaging; Retrospec | 2022 |
Inequities in Therapy for Infantile Spasms: A Call to Action.
Topics: Black People; Child; Hispanic or Latino; Humans; Prospective Studies; Spasms, Infantile; Vigabatrin | 2022 |
Treatment of Infantile Spasm Syndrome: Update from the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society of Neuropediatrics.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Epilepsy; Humans; Infant; Spasms, Infantile; Syndrome; | 2022 |
Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cognition; Electroencephalography; Humans; Infant; Spa | 2022 |
Prioritizing Hormone Therapy Over Vigabatrin as the First Treatment for Infantile Spasms: A Quality Improvement Initiative.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Cohort Studies; Humans; Infant; Pred | 2022 |
Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.
Topics: Anticonvulsants; Humans; Infant; Prednisolone; Recurrence; Retrospective Studies; Spasm; Spasms, Inf | 2022 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Partial Efficacy of Vigabatrin in an Infant With West Syndrome Due to Pyruvate Dehydrogenase Complex Deficiency: A Case Report.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyruvate Dehydrogenase Complex Deficie | 2023 |
Epileptic spasms related to neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and high dose prednisolone therapy.
Topics: Anticonvulsants; Basic Helix-Loop-Helix Transcription Factors; Female; Humans; Infant; Mutation; Neu | 2022 |
Epileptic spasms related to neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and high dose prednisolone therapy.
Topics: Anticonvulsants; Basic Helix-Loop-Helix Transcription Factors; Female; Humans; Infant; Mutation; Neu | 2022 |
Epileptic spasms related to neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and high dose prednisolone therapy.
Topics: Anticonvulsants; Basic Helix-Loop-Helix Transcription Factors; Female; Humans; Infant; Mutation; Neu | 2022 |
Epileptic spasms related to neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and high dose prednisolone therapy.
Topics: Anticonvulsants; Basic Helix-Loop-Helix Transcription Factors; Female; Humans; Infant; Mutation; Neu | 2022 |
Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child; Female; Humans; Infant; Infant, Newborn; Male; | 2023 |
Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials.
Topics: Anticonvulsants; Cosyntropin; Epilepsy; Humans; Infant; Prednisolone; Randomized Controlled Trials a | 2023 |
A case of Aicardi syndrome associated with duplication event of Xp22 including
Topics: Aicardi Syndrome; Anticonvulsants; Child; Child, Preschool; Female; Humans; Retina; Short Stature Ho | 2023 |
Rapid determination of plasma vigabatrin by LC-ESI-MS/MS supporting therapeutic drug monitoring in children with infantile spasms.
Topics: Adult; Child; Chromatography, Liquid; Drug Monitoring; Humans; Spasms, Infantile; Tandem Mass Spectr | 2023 |
Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Female; Humans; Infant; Male; | 2023 |
Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting.
Topics: Electroencephalography; Humans; Infant; Spasm; Spasms, Infantile; Vigabatrin | 2023 |
What Should be the Next Choice After Failure of Hormonal and Vigabatrin Therapy in Infantile Epileptic Spasms Syndrome?
Topics: Anticonvulsants; Humans; Infant; Spasm; Spasms, Infantile; Syndrome; Treatment Outcome; Vigabatrin | 2023 |
Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.
Topics: Anticonvulsants; Brazil; Child; Consensus; Epilepsy; Humans; Infant; Prednisolone; Recurrence; Spasm | 2023 |
The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (ICISS).
Topics: Anticonvulsants; Female; Humans; Infant; Male; Malformations of Cortical Development; Prednisolone; | 2019 |
X-Linked ALG13 Gene Variant as a Cause of Epileptic Encephalopathy in Girls.
Topics: Brain; Exome; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; India; Infant; M | 2019 |
Topiramate as an Adjunct in the Management of West Syndrome.
Topics: Anticonvulsants; Drug Tolerance; Female; Humans; India; Infant; Male; Prospective Studies; Spasms, I | 2020 |
Retinal defect in children with infantile spasms of varying etiologies: An observational study.
Topics: Anticonvulsants; Child, Preschool; Electroretinography; Female; Genetic Diseases, Inborn; Humans; Hy | 2020 |
Compliance With Standard Therapies and Remission Rates After Implementation of an Infantile Spasms Management Guideline.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Female; Glucocorticoids; Guideline Adherence; Humans; | 2020 |
Felbamate in the treatment of refractory epileptic spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Felbamate; Female; Humans; Infant; M | 2020 |
ACTON PROLONGATUM® suppresses spasms head to head with Acthar® Gel in the model of infantile spasms.
Topics: Adrenocorticotropic Hormone; Amino Acid Sequence; Animals; Animals, Newborn; Anticonvulsants; Diseas | 2020 |
Complete resolution of epileptic spasms with vigabatrin in a patient with 3-methylglutaconic aciduria caused by TIMM50 gene mutation.
Topics: Female; Humans; Infant; Membrane Transport Proteins; Metabolism, Inborn Errors; Mitochondrial Precur | 2020 |
Prophylactic Antiepileptic Treatment in Tuberous Sclerosis.
Topics: Anticonvulsants; Humans; Prospective Studies; Spasms, Infantile; Tuberous Sclerosis; Vigabatrin | 2020 |
Crisis Standard of Care: Management of Infantile Spasms during COVID-19.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Betacoronavirus; Coronavirus Infections; COVID-19; Del | 2020 |
Disparate effects of hormones and vigabatrin on sleep slow waves in patients with West syndrome - An indication of their mode of action?
Topics: Anticonvulsants; Electroencephalography; Female; Hormones; Humans; Infant; Longitudinal Studies; Mal | 2021 |
Teaching NeuroImages: Reversible neuroimaging findings during treatment of infantile spasms with vigabatrin.
Topics: Anticonvulsants; Brain; Humans; Infant; Magnetic Resonance Imaging; Male; Neurology; Spasms, Infanti | 2020 |
West syndrome: A study of 26 patients receiving short-term therapy.
Topics: Adrenocorticotropic Hormone; Child; Electroencephalography; Female; Humans; Infant; Male; Seizures; | 2021 |
Infantile spasms and COVID-19: Challenges and solutions in resource-limited settings.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Betacoronavirus; Coronavirus Infections; COVID-19; Del | 2020 |
Management of West syndrome during COVID-19 pandemic: A viewpoint from South Asian West Syndrome Research Group.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Antiviral Agents; Betacoronav | 2020 |
Vigabatrin Toxicity in a Patient with Infantile Spasms Treated with Concomitant Hormonal Therapy.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain; Brain Diseases; Drug Therapy, Combination; Fema | 2020 |
Hippocampal Involvement With Vigabatrin-Related MRI Signal Abnormalities in Patients With Infantile Spasms: A Novel Finding.
Topics: Anticonvulsants; Female; Hippocampus; Humans; Infant; Magnetic Resonance Imaging; Male; Retrospectiv | 2021 |
Infantile Spasms and Trisomy 21: Unfavorable Outcomes with First-line Vigabatrin Therapy.
Topics: Anticonvulsants; Child; Down Syndrome; Humans; Infant; Retrospective Studies; Spasms, Infantile; Tre | 2021 |
Neurodevelopmental and epilepsy outcomes of patients with infantile spasms treated in a tertiary care center.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Drug Therapy, Combination; Female; Humans; Infant; Inf | 2021 |
Disparate treatment outcomes according to presence of pathogenic mutations in West syndrome.
Topics: Age of Onset; Anti-Inflammatory Agents; Anticonvulsants; Arrhythmias, Cardiac; Child; Child, Prescho | 2021 |
Treatment with High-Dose Prednisolone in Vigabatrin-Refractory Infantile Spasms.
Topics: Anticonvulsants; Child; Humans; Infant; Prednisolone; Spasms, Infantile; Treatment Outcome; Vigabatr | 2022 |
West Syndrome in Children With Congenital Zika Virus Infection.
Topics: Anticonvulsants; Ecuador; Female; Humans; Infant; Male; Microcephaly; Phenotype; Pregnancy; Pregnanc | 2021 |
Medication selection, health services outcomes, and cost trajectories for Medicaid beneficiaries with infantile spasms.
Topics: Anticonvulsants; Child; Health Services; Humans; Infant; Medicaid; Retrospective Studies; Spasms, In | 2021 |
What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?
Topics: Anticonvulsants; Child; Humans; Infant; Prospective Studies; Retrospective Studies; Spasm; Spasms, I | 2021 |
Auditory processing following infantile spasms: An event-related potential study.
Topics: Acoustic Stimulation; Auditory Pathways; Auditory Perception; Case-Control Studies; Cerebral Cortex; | 2017 |
Hormonal therapy with vigabatrin is superior to hormonal therapy alone in infantile spasms.
Topics: Humans; Research Design; Spasms, Infantile; Vigabatrin | 2017 |
The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium.
Topics: Adrenocorticotropic Hormone; Age of Onset; Anticonvulsants; Cohort Studies; Female; Humans; Infant; | 2017 |
Recognition of Infantile Spasms Is Often Delayed: The ASSIST Study.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Clinical Competence; Delayed | 2017 |
Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Electroencephalography; Female; Huma | 2018 |
White matter spongiosis with vigabatrin therapy for infantile spasms.
Topics: Anticonvulsants; Brain Edema; Child, Preschool; Fatal Outcome; Humans; Infant, Newborn; Male; Spasms | 2018 |
Globus pallidus restricted diffusion associated with vigabatrin therapy.
Topics: Anticonvulsants; Basal Ganglia Diseases; Diffusion Magnetic Resonance Imaging; Female; Globus Pallid | 2018 |
Vigabatrin and high-dose prednisolone therapy for patients with West syndrome.
Topics: Anti-Inflammatory Agents; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug | 2018 |
Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Male; Spasms, Infantil | 2016 |
Strength and stability of EEG functional connectivity predict treatment response in infants with epileptic spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain Waves; Cortical Synchronization; Female; Humans; | 2018 |
Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data.
Topics: Adult; Anticonvulsants; Biological Availability; Child; Child, Preschool; Female; Humans; Infant; Ma | 2019 |
Precious time to respond to infantile spasms.
Topics: Adrenocorticotropic Hormone; Humans; Spasm; Spasms, Infantile; Vigabatrin | 2018 |
High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Prospective Studies | 2018 |
High-Dose Prednisolone as a First-line Treatment for Infantile Spasms.
Topics: Adrenal Cortex Hormones; Child; Humans; Prednisolone; Retrospective Studies; Spasms, Infantile; Viga | 2018 |
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
Vigabatrin as a Targeted Treatment of GABA
Topics: Animals; Anticonvulsants; Chromosomes, Human, Pair 9; Drug Substitution; Electroencephalography; Epi | 2019 |
Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Clinical Protocols; Cohort Studies; Disease Susceptibi | 2019 |
An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms.
Topics: Anticonvulsants; Basal Ganglia; Brain; Brain Stem; Cerebellum; Female; Globus Pallidus; Humans; Infa | 2013 |
Prognostic factors of infantile spasms: role of treatment options including a ketogenic diet.
Topics: Anticonvulsants; Diet, Ketogenic; Electroencephalography; Female; Humans; Infant; Male; Retrospectiv | 2013 |
A novel mutation in STXBP1 gene in a child with epileptic encephalopathy and an atypical electroclinical pattern.
Topics: Amino Acid Sequence; Anticonvulsants; Brain; Child, Preschool; Electroencephalography; Humans; Infan | 2014 |
Reversible vigabatrin-induced life-threatening encephalopathy.
Topics: Anticonvulsants; Brain; Brain Diseases; Female; Humans; Infant; Magnetic Resonance Imaging; Spasms, | 2014 |
Adrenocorticotropic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cohort Studies; Female; Humans; Infant; Male; Predniso | 2015 |
Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.
Topics: Anticonvulsants; Child; Child, Preschool; Electroretinography; Female; Humans; Infant; Male; Photic | 2014 |
Analysis of vigabatrin treatment causing visual field defects in infantile spasms.
Topics: Anticonvulsants; Female; Humans; Male; Spasms, Infantile; Vigabatrin; Vision Disorders; Visual Field | 2015 |
Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Female; Humans; Infant; | 2015 |
Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms.
Topics: Adult; Body Weight; Child; Child, Preschool; Enzyme Inhibitors; Epilepsy; Female; gamma-Aminobutyric | 2014 |
Practice experience in the treatment of infantile spasms at a tertiary care center.
Topics: Anticonvulsants; Child, Preschool; Cohort Studies; Databases, Factual; Electroencephalography; Femal | 2014 |
Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients.
Topics: Adolescent; Anticonvulsants; Chi-Square Distribution; Child; Child, Preschool; Cohort Studies; Femal | 2014 |
Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.
Topics: Anticonvulsants; Child; Child, Preschool; Cohort Studies; Electroretinography; Female; Follow-Up Stu | 2014 |
Epileptic spasms without hypsarrhythmia in infancy and childhood: tonic spasms as a seizure type.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Epilepsies, Partial; Humans; Infant; Male; Oxcarba | 2015 |
Long-term outcome in children with infantile spasms treated with vigabatrin: A cohort of 180 patients.
Topics: Anticonvulsants; Female; Humans; Male; Spasms, Infantile; Vigabatrin | 2015 |
In response to: Long-term outcome in children with infantile spasms treated with vigabatrin: A cohort of 180 patients.
Topics: Anticonvulsants; Female; Humans; Male; Spasms, Infantile; Vigabatrin | 2015 |
Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms.
Topics: Animals; Anticonvulsants; Brain Mapping; Disease Models, Animal; Electroencephalography; Humans; Inf | 2015 |
Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diet, Ketogenic; Epilepsies, Partial; Epilepsy | 2015 |
Unintended Consequences: The Story of PERF.
Topics: Adult; Anticonvulsants; Drug Approval; Epilepsy; Foundations; History, 20th Century; Humans; Infant; | 2015 |
Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies | 2015 |
Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.
Topics: Anticonvulsants; Female; Humans; Male; Retinal Diseases; Spasms, Infantile; Vigabatrin | 2015 |
Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.
Topics: Anticonvulsants; Ataxia; Electroencephalography; Female; Humans; Infant; Magnetic Resonance Imaging; | 2015 |
Author Response.
Topics: Anticonvulsants; Female; Humans; Male; Retinal Diseases; Spasms, Infantile; Vigabatrin | 2015 |
[West syndrome: about an observation].
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Spasms, Infantile; Vigabatrin | 2015 |
Reversible MRI Changes in an Infant with Epileptic Spasms on Low Dose Vigabatrin.
Topics: Anticonvulsants; Electroencephalography; Enzyme Inhibitors; Humans; Infant; Magnetic Resonance Imagi | 2016 |
A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
Topics: Anticonvulsants; California; Child; Child, Preschool; Cohort Studies; Electroencephalography; Female | 2016 |
Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Complex Partial; Female; Humans; Infant; Male; Registr | 2016 |
Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit.
Topics: Cohort Studies; Electroencephalography; Female; Fructose; Humans; Infant; Isoxazoles; Male; Recurren | 2016 |
Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cohort Studies; Female; Humans; Infant; Male; Spasms, | 2016 |
Vigabatrin Therapy for Infantile Spasms in a Case of Cardiofaciocutaneous Syndrome with Cardiac Hypertrophy Developing during Adrenocorticotropic Hormone Treatment.
Topics: Adrenocorticotropic Hormone; Cardiomegaly; Child, Preschool; Ectodermal Dysplasia; Electrocardiograp | 2016 |
Combination therapy for treatment of infantile spasms.
Topics: Anticonvulsants; Combined Modality Therapy; Humans; Spasms, Infantile; Vigabatrin | 2017 |
Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity?
Topics: Anticonvulsants; Autophagy; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Humans; Infant; Infa | 2017 |
Neuroimaging Abnormalities in a Child With Infantile Spasms on High-Dose Vigabatrin.
Topics: Developmental Disabilities; Down Syndrome; Dyskinesia, Drug-Induced; Female; GABA Agents; Humans; In | 2017 |
[Reversible alterations in the neuroimages associated with vigabatrine treatment in infants with epileptic spasms].
Topics: Anticonvulsants; Brain; Drug Resistance; Drug Resistant Epilepsy; Humans; Infant; Magnetic Resonance | 2017 |
Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent.
Topics: Anticonvulsants; Brain; Child, Preschool; Dose-Response Relationship, Drug; Electroencephalography; | 2017 |
Cerebral MRI abnormalities associated with vigabatrin therapy.
Topics: Adolescent; Anticonvulsants; Brain; Brain Edema; Child; Child, Preschool; Diffusion Magnetic Resonan | 2009 |
Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anticonvulsants; Child; Child, Preschool; DNA Mutati | 2009 |
A retrospective study on aetiology based outcome of infantile spasms.
Topics: Anticonvulsants; Cognition Disorders; Developmental Disabilities; Electroencephalography; Female; Fo | 2009 |
Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Child; Child, Preschool; Cross-Sectional Studies; Diffusi | 2009 |
Infantile spasms and Down syndrome: a new animal model.
Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; E | 2009 |
Visual fields at school-age in children treated with vigabatrin in infancy.
Topics: Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Sche | 2009 |
Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
Topics: Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Evoked Potentials, Visual; Female; H | 2009 |
Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin.
Topics: Adolescent; Adrenocorticotropic Hormone; Age of Onset; Anticonvulsants; Brain; Child; Child Developm | 2009 |
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroencephalography; F | 2010 |
Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
Topics: Adult; Anticonvulsants; Child; Disease Progression; Humans; Infant; Perceptual Disorders; Spasms, In | 2009 |
Vigabatrin therapy in infantile spasms: solving one problem and inducing another?
Topics: Adolescent; Anticonvulsants; Child; Female; Follow-Up Studies; Humans; Infant; Male; Retrospective S | 2009 |
Early infantile epileptic encephalopathy with unusual favourable outcome.
Topics: Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Infant; Male; Pre | 2010 |
Drug approved to treat infantile spasms.
Topics: Anticonvulsants; Drug Approval; Humans; Infant; Product Labeling; Spasms, Infantile; United States; | 2009 |
Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.
Topics: Anticonvulsants; Brain; Brain Damage, Chronic; Causality; Cerebral Palsy; Demyelinating Diseases; Di | 2009 |
Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Disease Models, Animal; E | 2010 |
A model of symptomatic infantile spasms syndrome.
Topics: Adrenocorticotropic Hormone; Animals; Animals, Newborn; Antibiotics, Antineoplastic; Anticonvulsants | 2010 |
Therapy of infantile spasms: new opportunities and emerging challenges.
Topics: Anticonvulsants; Humans; Infant; Risk Assessment; Spasms, Infantile; Vigabatrin | 2010 |
Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Developmental Disabilities; F | 2010 |
Infantile spasms: who are the ideal surgical candidates?
Topics: Anticonvulsants; Brain; Electroencephalography; Humans; Infant; Isoxazoles; Magnetic Resonance Imagi | 2010 |
Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms.
Topics: Child; Child, Preschool; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Humans; In | 2010 |
Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants.
Topics: Adrenal Cortex Hormones; Diet, Ketogenic; Electroencephalography; Female; Humans; Infant; Male; Pred | 2010 |
Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Infant; Spasms, Infantile; Vigabatrin; Vision Disorders; V | 2010 |
Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin.
Topics: Anticonvulsants; Brain Stem; Diffuse Axonal Injury; Female; Humans; Infant; Magnetic Resonance Imagi | 2011 |
Infantile spasms: toward a selective diagnostic and therapeutic approach.
Topics: Anticonvulsants; Consensus; Electroencephalography; Humans; Hypoxia-Ischemia, Brain; Infant; Spasms, | 2010 |
The Japanese scheme of ACTH therapy in West syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cosyntropin; Cross-Cultural Comparison; Dose-Response | 2010 |
Reversible magnetic resonance imaging and spectroscopy abnormalities in the course of vigabatrin treatment for West syndrome.
Topics: Anticonvulsants; Basal Ganglia Diseases; Brain Diseases, Metabolic; Chronic Disease; Humans; Infant; | 2011 |
Vigabatrin administration in patients with infantile spasms: the risks.
Topics: Anticonvulsants; Humans; Infant; Magnetic Resonance Imaging; Spasms, Infantile; Vigabatrin | 2010 |
[Epileptic spasms without hypsarrhythmia. A new case report and review of the literature].
Topics: Anticonvulsants; Diagnosis, Differential; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2010 |
A European perspective—comments on "Infantile spasms: a U.S. consensus report".
Topics: Adrenocorticotropic Hormone; Consensus; Consensus Development Conferences as Topic; Cross-Cultural C | 2010 |
[Effectiveness of vigabatrin in west syndrome associated with tuberous sclerosis].
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Male; Spasms, Infantile; Tuberous S | 2010 |
[West syndrome: aetiology, therapeutic options, clinical course and prognostic factors].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Femal | 2011 |
Seizure outcome in infantile spasms--a retrospective study.
Topics: Anticonvulsants; Female; Humans; Infant, Newborn; Male; Outcome Assessment, Health Care; Retrospecti | 2011 |
[Aicardi syndrome associated with severe congenital ptosis].
Topics: Agenesis of Corpus Callosum; Aicardi Syndrome; Anticonvulsants; Blepharoptosis; Brain; Cerebellum; D | 2011 |
Validation of the rat model of cryptogenic infantile spasms.
Topics: Adrenocorticotropic Hormone; Animals; Animals, Newborn; Betamethasone; Disease Models, Animal; Elect | 2011 |
Angelman syndrome and pseudo-hypsarrhythmia: a diagnostic pitfall.
Topics: Angelman Syndrome; Anticonvulsants; Chromosome Deletion; Chromosomes, Human, Pair 15; Diagnosis, Dif | 2011 |
Screening for vigabatrin (Sabril ®) retinal toxicity in children.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Child; Child, Preschool; Enzyme Inhibitors; Epileps | 2011 |
Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.
Topics: Adult; Anticonvulsants; Epilepsies, Partial; History, 20th Century; History, 21st Century; Humans; I | 2011 |
Measuring field loss in children administered vigabatrin: a problem in search of a solution.
Topics: Anticonvulsants; Child; Humans; Infant; Spasms, Infantile; Time Factors; Vigabatrin; Vision Disorder | 2011 |
The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Awards and Prizes; Cocaine-Related Disorders | 2012 |
Vigabatrin for childhood partial-onset epilepsies.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Partial; Female; Follow-Up | 2012 |
T2 hyperintense signal of the central tegmental tracts in children: disease or normal maturational process?
Topics: Adolescent; Anticonvulsants; Case-Control Studies; Child; Child, Preschool; Comorbidity; Female; Hum | 2012 |
Treatment of West syndrome with vigabatrin: reversible MRI signal changes.
Topics: Anticonvulsants; Brain; Humans; Infant; Magnetic Resonance Imaging; Spasms, Infantile; Vigabatrin | 2011 |
Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Electroencephalography; Female; Humans; Infant; Male; | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Spasms, Infan | 2012 |
Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures.
Topics: Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Intellectual Disa | 2013 |
Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin.
Topics: Anticonvulsants; Carbamazepine; Drug Resistance; Electroencephalography; Humans; Infant; Male; Neuro | 2012 |
Vigabatrin-related magnetic resonance imaging abnormalities in an infant with tuberous sclerosis complex and infantile spasms.
Topics: Enzyme Inhibitors; Humans; Infant; Magnetic Resonance Imaging; Spasms, Infantile; Tuberous Sclerosis | 2013 |
Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms?
Topics: Acute Disease; Anticonvulsants; Basal Ganglia Diseases; Down Syndrome; Dystonia; Humans; Infant; Mag | 2013 |
Randomized trial of vigabatrin in patients with infantile spasms.
Topics: Child; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Infant; Randomize | 2002 |
Low-dose lamotrigine in West syndrome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Electroencephalography; Female; Huma | 2002 |
Vigabatrin for infantile spasms.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combi | 2002 |
Vigabatrin therapy in infantile spasms.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Female; Follow-Up Studies; Humans; Infant | 2002 |
Treatment of infantile spasms: the ideal and the mundane.
Topics: Anticonvulsants; Drug Administration Schedule; Humans; Infant; Nitrazepam; Spasms, Infantile; Vigaba | 2003 |
Short-term nonhormonal and nonsteroid treatment in West syndrome.
Topics: Anticonvulsants; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Administration Schedule; El | 2003 |
Longitudinal changes in photopic OPs occurring with vigabatrin treatment.
Topics: Anticonvulsants; Child, Preschool; Electroretinography; Follow-Up Studies; Humans; Infant; Photic St | 2003 |
Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.
Topics: Anticonvulsants; Child, Preschool; Dark Adaptation; Electroretinography; Humans; Infant; Oscillometr | 2003 |
[Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis].
Topics: Age of Onset; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Follow-Up St | 2003 |
Early treatment of Aicardi syndrome with vigabatrin can improve outcome.
Topics: Anticonvulsants; Corpus Callosum; Female; Humans; Infant; Magnetic Resonance Imaging; Spasms, Infant | 2004 |
Reduced visual function associated with infantile spasms in children on vigabatrin therapy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Evoked Potentials | 2005 |
[Treatment of West syndrome].
Topics: Anticonvulsants; Cosyntropin; Delayed-Action Preparations; Female; Humans; Infant; Infant, Newborn; | 2005 |
[Efficacy and tolerability of vigabatrin in West syndrome].
Topics: Anticonvulsants; Child; Child, Preschool; Female; GABA Agents; Humans; Infant; Male; Retinal Disease | 2005 |
[Infantile spasms].
Topics: Glucocorticoids; Humans; Infant, Newborn; Prognosis; Spasms, Infantile; Vigabatrin | 2005 |
A plausible explanation for superiority of adreno-cortico-trophic hormone (ACTH) over oral corticosteroids in management of infantile spasms (West syndrome).
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Cortico | 2006 |
D-bifunctional protein deficiency associated with drug resistant infantile spasms.
Topics: 17-Hydroxysteroid Dehydrogenases; Anticonvulsants; Disease Progression; DNA Mutational Analysis; Dru | 2007 |
Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?
Topics: Cerebral Cortex; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; H | 2007 |
[Treatment of West syndrome with vigabatrin: clinical and electroencephalographic evaluation of 13 patients].
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant; Male; Prospective Studies; Spasms, | 2007 |
Drug-choice in management of West syndrome (infantile spasms): Early ACTH treatment may offer a better prognostic outcome.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Prognosis; Spasms, Infantile; Vigabatr | 2008 |
Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Infant; Prospective Studies; Spasms, Infa | 2007 |
Infantile spasms and cytomegalovirus infection: antiviral and antiepileptic treatment.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Inf | 2007 |
Treatment of infantile spasms with sodium valproate followed by benzodiazepines.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Benzodiazepines; Clonazepam; Drug Therapy, Combination | 2007 |
Treatment of infantile spasms with sodium valproate followed by benzodiazepines.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Benzodiazepines; Clonazepam; Drug Therapy, Combination | 2007 |
The management of infantile spasms.
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Diagnosis, Differential; Dose-Response | 2008 |
[Epileptic seizures in childhood: from seizure type to diagnosis].
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Diagnosis, Differential; Electroencephalography; Ep | 2008 |
Management of epilepsy in tuberous sclerosis complex.
Topics: Anticonvulsants; Child; Drug Resistance; Epilepsy; Gene Expression; Humans; Infant; Prognosis; Prote | 2008 |
Management of infantile spasms in a regional centre before and after the United Kingdom infantile spasms study (UKISS).
Topics: Anticonvulsants; England; Humans; Infant; Medical Audit; Spasms, Infantile; Steroids; Vigabatrin | 2008 |
Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Topics: Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroretinography; Epilepsies, Part | 2008 |
Vigabatrin monotherapy in resistant neonatal seizures.
Topics: Agenesis of Corpus Callosum; Anticonvulsants; Atrophy; Brain; Cerebral Cortex; Dose-Response Relatio | 1995 |
'A simple, effective and well-tolerated treatment regime for West Syndrome'.
Topics: Anticonvulsants; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Humans; Infant; Male; Spasms, I | 1995 |
Vigabatrin in the treatment of infantile spasms.
Topics: Aminocaproates; Anticonvulsants; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Administrat | 1993 |
The treatment of infantile spasms by paediatric neurologists in the UK and Ireland.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Anticonvulsants; gamma-Aminobutyric Acid; Hum | 1996 |
[Vigabatrin in the treatment of infantile spasms].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Male; Spasms, | 1995 |
[Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients].
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; gamma-Aminobutyric Ac | 1996 |
[West's syndrome in patients with cerebral paralysis and periventricular leukomalacia: a good response to treatment].
Topics: Anticonvulsants; Atrophy; Cerebral Palsy; Cerebral Ventricles; Child; Child, Preschool; Female; gamm | 1997 |
[Monotherapy with vigabatrin in the treatment of West's syndrome].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Infant; Male; | 1997 |
Falsely elevated urinary ethanolamine levels due to vigabatrin.
Topics: Anticonvulsants; Child, Preschool; Developmental Disabilities; Ethanolamine; Female; gamma-Aminobuty | 1998 |
[Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants].
Topics: Anti-Inflammatory Agents; Anticonvulsants; Drug Administration Schedule; Female; gamma-Aminobutyric | 1998 |
Infantile spasms and vigabatrin. Study will compare effects of drugs.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Infant; Publishing; Spasms, Infantile; Vigabatrin | 1999 |
Infantile spasms and vigabatrin. Visual field defects may be permanent.
Topics: Adult; Anticonvulsants; Child; gamma-Aminobutyric Acid; Humans; Infant; Practice Guidelines as Topic | 1999 |
Vigabatrin in the treatment of infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Drug Resistance; Electroencephalography; Female; gamma | 1999 |
Is the devil we know the lesser of two evils? Vigabatrin and visual fields.
Topics: Adrenocorticotropic Hormone; gamma-Aminobutyric Acid; Humans; Spasms, Infantile; Vigabatrin; Visual | 1999 |
ACTH versus vigabatrin therapy in infantile spasms: a retrospective study.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Infant; Male; | 1999 |
[The usefulness of statistical tests in publications].
Topics: 4-Aminobutyrate Transaminase; Anti-Inflammatory Agents; Anticonvulsants; Chi-Square Distribution; En | 1999 |
Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.
Topics: Anticonvulsants; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Drug Therapy, Com | 2000 |
Acute encephalopathy associated with vigabatrin in a six-month-old girl.
Topics: Acute Disease; Age Factors; Anticonvulsants; Brain Diseases; Electroencephalography; Female; Humans; | 2000 |
[Infantile spasms: experience in 13 cases].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Female; Humans; Infant; Male; Prognosis; Recurrence; S | 2000 |
Revised guideline for prescribing vigabatrin in children. Guideline's claim about infantile spasms is not based on appropriate evidence.
Topics: Anticonvulsants; Evidence-Based Medicine; Humans; Infant; Practice Guidelines as Topic; Spasms, Infa | 2001 |
The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 2001 |
The use of vigabatrin in infantile spasms in Asian children.
Topics: Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 2001 |
National survey on West syndrome in Korea.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Data Collection; Female; Humans; Incidence; Infant; Ko | 2001 |
National survey of West syndrome in Taiwan.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Data Collection; Female; Humans; Incidence; Infant; In | 2001 |
West syndrome: a university hospital based study from Oman.
Topics: Anticonvulsants; Child, Hospitalized; Electroencephalography; Female; Follow-Up Studies; Humans; Inf | 2001 |
West syndrome--The University of Hong Kong experience (1970-2000).
Topics: Anticonvulsants; Child, Hospitalized; Child, Preschool; Female; Hong Kong; Humans; Incidence; Infant | 2001 |
Epidemiologic features of infantile spasms in Slovenia.
Topics: Adrenocorticotropic Hormone; Age of Onset; Anticonvulsants; Female; Humans; Hydrocortisone; Incidenc | 2002 |
Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin).
Topics: Age Factors; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; | 1992 |
Therapeutic trial of vigabatrin in refractory infantile spasms.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Vigabatrin in infantile spasms.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Drug Evaluation; Humans; Infan | 1990 |